2025 Poster Session Abstracts
Poster abstracts are organized below by their position in the hall.
Charlisa Whyms1, Yu Zhao2, Doreen Addo-Yobo1, Huan He1, Arthur Carl Whittington3, Despoina Trasanidou4, Carl Raymund P. Salazar4, Raymond H.J. Staals4, and Hong Li1,2 *
Department of Chemistry and Biochemistry1, Institute of Molecular Biophysics2, Department of Biological Sciences3, Florida State University, Tallahassee, FL 32306, USA.
Laboratory of Microbiology, Wageningen University and Research4, Stippeneng 4, 6708WE Wageningen, The Netherlands.
Abstract:
CRISPR-Cas systems provide prokaryotes with adaptive immunity against invading mobile genetic elements. These systems employ a diverse array of effector proteins to combat infection. Our research focuses on Cad1, a unique CRISPR-associated Rossman-fold (CARF) protein that exhibits adenosine deaminase (ADA) activity upon viral invasion. Unlike other CARF proteins that directly target nucleic acids, Cad1 catalyzes the conversion of ATP to ITP when bound with a cyclic oligoadenylate (cOA) produced by the virus-activated CRISPR-Csm system. Structural analysis of Cad1 bound with or without cOA and ATP reveals that while Cad1 shares similarities with canonical ADA enzymes, it possesses distinct features that dictate its specificity for ATP. Furthermore, we demonstrate an allosteric link between the cOA-binding CARF domain and the ADA domain, suggesting that cOA signaling directly regulates Cad1 activity. This intricate regulatory mechanism points to a role for Cad1 in modulating cellular metabolism during viral infection. Interestingly, while Cad1 exhibits robust ADA activity in vitro, our in vivo assay reveals a mild contribution to prokaryotic defense. These findings suggest that Cad1 may play a nuanced role in the CRISPR-Cas immune response, possibly through subtle metabolic reprogramming.
Lei Han, Dayang Huang, Shiyong Wu, Sheng Liu, Cheng Wang, Jun Wan, Lei Yang
Indiana University School of Medicine, Indianapolis, IN, 46202, USA
Abstract:
Lipid droplets (LDs) are dynamic organelles in both prokaryotic and eukaryotic cells, playing crucial roles in lipid storage, trafficking, and cellular homeostasis. Synthesized in the endoplasmic reticulum, LDs consist of a neutral lipid core, primarily triacylglycerols and sterol esters, and surrounded by a phospholipid monolayer. Under hyperlipidemic conditions, LDs accumulate in the heart to store excess fatty acids, displaying a transient protective role. However, sustained LD accumulation is associated with cardiomyopathies and heart failure, particularly in individuals with metabolic disorders, such as obesity and diabetes mellitus. Currently, the mechanisms of LD transportation in human cardiomyocytes have not been well understood.
Here, we identify Lipid-Droplet Transporter (LIPTER), a long non-coding RNA, as a key mediator of LD transportation in human cardiomyocytes. LIPTER interacts with phosphatidic acid and phosphatidylinositol 4-phosphate on the LD surface and the MYH10 protein, thereby connecting LDs to the MYH10-ACTIN cytoskeleton to facilitate LD transport. Disruption of either LIPTER or MYH10 impairs LD trafficking, mitochondrial function and survival of human iPS cell-derived cardiomyocytes (hiPSC-CMs). Moreover, conditional deletion of Myh10 in mouse cardiomyocytes resulted in LD accumulation, and compromised cardiac function. Importantly, LIPTER transgenic expression could mitigate cardiac lipotoxicity in hiPSC-CMs, preserve cardiac function and alleviate cardiomyopathies in high-fat-diet-fed and Leprdb/db mice. Overall, these findings unveil a pivotal role of LIPTER in LD transport within human cardiomyocytes, crucial for cardiac lipid homeostasis of human heart. This work highlights the potential of LIPTER as a therapeutic strategy for treating metabolic syndrome-associated heart disease and heart failure.
Nicholas Rice1, Sean McCauley1, Kyle Foster1, Parixit Oza1, Hannah McCauley1, Sarah Goudreau1, Alexey Wolfson1
ADViRNA1 17 Briden Street Worcester, MA 01605
Abstract:
Oligonucleotide therapeutics are rapidly becoming a major class of drugs, with several compounds already approved, tens more in the late stages of clinical development, and hundreds more in preclinical stage. The ability to efficiently measure therapeutic oligonucleotide concentration in blood and target tissues/organs is essential for PK/PD studies. The currently available methods such as HPLC-based hybridization assay or mass-spectrometry are either low throughput or require sophisticated equipment and substantial optimization in setting up detection protocols. Several attempts have been made to develop ELISA-like hybridization detection protocols, but none have been widely implemented due to the requirement for non-standard reagents, extensive assay optimization or limitations in efficacy due to the nature of oligonucleotides (i.e. single-stranded vs double stranded, chemical modifications, etc). By optimizing the hybridization conditions, the enzymatic ligation and standardizing the chemical nature of the capture probe we have developed a robust ELISA-like assay based on a hybridization-ligation approach. The assay design utilizes commonly commercially available reagents and can be easily customized for any oligonucleotide analyte with a simple sequence modification of the capture probe. The detection range of the assay ranges from 1 to 1000 fmol in plasma and tissue extracts. Implementation of this assay can significantly improve and facilitate PK/PD studies of therapeutic oligonucleotides while substantially reducing costs. We describe applications of the assay for the measurement of fully modified siRNAs concentrations in cultured cells and animal tissue samples.
Wenxi Yu1*, Sophie F. Hill1,2, Yumei Huang3, Limei Zhu4, Yiannos Demetriou4, Julie Ziobro5, Faith Reger1, Xiaoyan Jia3, Joanna Mattis4, and Miriam H. Meisler1,2
1Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA
2Neuroscience Graduate Program, University of Michigan, Ann Arbor, Michigan, USA
3Center for Genomic Technologies, Greater Bay Area Institute of Precision Medicine (Guangzhou), Fudan University, Guangzhou, Guangdong, China
4Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA
5Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA
Abstract:
Silencing a dominant pathogenic allele using Crispr targeting in a heterozygous patient provides a general approach to therapy of dominant disorders. The success of this approach depends on identification of an sgRNA that targets the pathogenic allele but not the wildtype allele, so as to retain the function of the wildtype allele. Most sgRNAs with a single nucleotide difference between wildtype and mutant allele do not support allele-specific targeting. We therefore tested this approach in an animal model of epilepsy using an sgRNA with three bp difference between the wildtype and mutant alleles of the neuronal sodium channel gene SCN8A. Cas9 was provided by a ubiquitously expressed transgene (JAX 026179). The sgRNA was injected into the cerebral ventricles of neonatal mutant mice. We obtained 25% inactivation of the pathogenic allele, by generation of indels, compared with 0.5% indels in the wildtype allele. The high level of targeting was observed throughout the brain with the exception of cerebellum. Inactivation of the mutant allele resulted in reduced neuronal excitability. Mutant mice that were treated with sgRNA did not develop seizures and survived for more than 18 months, compared with seizures at 3 months and lethality at 5 months for the untreated mutant mice. This proof of principle experiment demonstrated that inactivation of the dominant allele in 25% of brain neurons was sufficient to prevent the spread of seizure activity. Future experiments will investigate the minimal % inactivation required for seizure protection, and effectiveness of delivery of sgRNA to specific brain regions.
Avinash Singh1; Kelly L Jordan-Sciutto1; Elena Alvarez Periel1;
1Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Abstract:
The accumulation of misfolded proteins in the endoplasmic reticulum (ER) leads to ER stress and is a trait of multiple neurodegenerative diseases. This leads to activation of the unfolded protein response (UPR) pathway, which coordinates three primary misfolded protein sensors (PERK, IRE1 and ATF6) to regulate different downstream mechanisms that resolve ER stress. Of these, PERK is responsible for downregulating global translation to limit ER stress and reestablish homeostasis; however, dysregulated PERK activation is a signature of neurodegeneration, suggesting its regulation is critical to proper cellular function and survival. Therefore, understanding PERK regulation is vital for targeting this pivotal pathway to reduce neurodegeneration. While PERK regulation at the protein level is well characterized, there is little research on its regulation at the transcriptional level. We set to investigate whether the PERK-coding gene EIF2AK3 undergoes alternative splicing (AS) and discovered three novel Eif2ak3 transcripts in rat primary neuronal cultures. Expression of these isoforms is increased in response to ER stress but not in the presence of other neuronal stressors, such as excitotoxicity. Further characterization also showed the prevalence of these isoforms in various brain regions (hippocampus, cortex, and striatum) and increased expression during embryonic stages. Finally, sequencing of these isoforms revealed that each resultant sequence introduces premature stop codons (PTCs). Thus, these sequences are predicted to activate the nonsense-mediated RNA decay pathway, which can couple with AS to regulate mRNA expression in the cell. These findings suggest alternative splicing of EIF2AK3 as a novel regulatory mechanism for PERK under ER stress.
Hunter O. Dunnuck, Laura M. Chamness, Patricia L. Clark, & Brittany S. Morgan
Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, 46556
Abstract:
RNA-binding proteins (RBPs) comprise approximately 20% of the human proteome and play significant roles in RNA regulation. Dysregulation of these RBPs has been implicated in various neurodegenerative diseases and cancers, making them vital targets for investigation. Many RBPs contain structurally conserved regions, particularly RNA binding domains such as RNA-recognition motifs (RRMs); however, due to structural conservation in RRMs, along with global protein disorder in other domains, non-covalent small molecule probes and inhibitors have failed to target these RBPs effectively. This project aims to identify the location of cysteine residues in RRMs, which can be harnessed for selective covalent ligand targeting. Cysteines in structurally unique locations will be identified using Multiple Sequence Alignments (MSAs) and structural analysis. This information will lead to prioritization of ideal RBP candidates for covalent ligand development, in addition to considering their disease relevance. Through a comprehensive literature review and UniProtKB search, 234 RBPs comprised of 408 RRMs were identified throughout the human proteome. MSAs and structural analyses revealed unexpected cysteine residues localized in clusters near the conserved ribonucleoprotein motifs (RNP1/RNP2) on beta-strands 2 and 3, which interact with RNA. These findings highlight the opportunities for selective covalent targeting of nucleophilic cysteine residues near essential RNA binding sites. Furthermore, we can pinpoint unique cysteine residues within RRMs and determine their targetability within specific secondary structure locations to aid in developing high-potency, selective covalent molecules for targeting unique and conserved cysteine residues.
Erika L. Ruskie (1), Michelle L. Hastings (1), Colin F. Greineder (1,2)
Department of Pharmacology (1), Department of Emergency Medicine (2), University of Michigan Medical School
Abstract:
Antisense oligonucleotides (ASOs) are chemically modified, short nucleotide sequences
that bind to RNA through complementary base-pairing to modulate gene expression,
with various mechanisms dependent on their design and modifications. ASOs
specifically target the genetic cause of diseases with minimal off-target effects, making
them increasingly valuable as therapeutics. However, ASOs cannot cross the blood-
brain barrier (BBB), necessitating direct delivery to the central nervous system (CNS),
typically via intrathecal injections. Modifications that enable peripherally administered
ASOs to reach the CNS would simplify delivery and advance the therapeutic utility of
this drug platform.
To address this challenge, we have optimized bispecific antibodies as a shuttling system
to transport ASOs across the BBB and reach deeper brain regions in a cell-specific
manner. These antibodies engage two targets: one on the vascular endothelial cell
membrane to facilitate transcytosis, and another on the surface of the target cell. By
attaching ASOs to bispecific antibodies, we aim to deliver them effectively and
specifically to neurons, microglia, and endothelial cells, enabling modulation of gene
expression in the CNS through systemic administration.
Our preliminary experiments, using a test ASO targeting the lncRNA, MALAT1, indicate
successful targeting of the expected cell populations of the CNS. Ultimately, our goal is
to develop ASOs that can treat a variety of conditions, enabling targeted gene
expression modulation within specific CNS cell populations.
Josean Alicea-Salas1, Michael Goldstein2, Elizabeth Pratico3, Michael Kastan4, Bruce Sullenger5, and Bethany Powell Gray1
Department of Pharmacology and Molecular Sciences1 and Department of Radiation Oncology2, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA; Moderna3, Cambridge, Massachusetts, 02142, USA; Duke Cancer Institute4 and Department of Surgery5, Duke University School of Medicine, Durham, North Carolina, 27710, USA
Abstract:
Endosomal escape remains a barrier for the delivery of oligonucleotide therapeutics, and there is a need for ligands that circumvent endosomal entrapment. The protein nucleolin (NCL) has been a target of interest for delivery into cancer cells since it was discovered that the G-quadruplex DNA aptamer AS1411 inhibits the growth of cancer cells. Although AS1411 is commonly referred to as a NCL-targeting aptamer, while the antiproliferative effects of AS1411 are dependent on NCL, the aptamer internalizes into cells via micropinocytosis in a manner independent of NCL. However, NCL remains an interesting target to circumvent endosomal entrapment and facilitate nuclear delivery of therapeutics. NCL is an essential, multifunctional nucleic acid-binding protein localized in the nucleolus that plays a critical role in the repair of DNA double-stranded breaks (DSBs). In cancerous cells, NCL is overexpressed on the plasma membrane and is aberrantly trafficked between the nucleoplasm, cytoplasm, and plasma membrane. Since NCL is such a promising target without a true aptamer ligand, we selected for an RNA aptamer capable of both binding NCL on a tumor cell surface and of subsequently translocating to the nucleus. To ensure both specificity for NCL and the ability to reach the nucleus, we combined a traditional protein SELEX with a Cell-Internalization SELEX method. Subsequent high-throughput sequencing identified NCL-binding RNA aptamers capable of internalizing into and localizing to the nucleus of cancer cells. Additionally, some of these aptamers disrupted DNA DSB repair, sensitizing the cells to radiation treatment.
Mitchell O Roth*1, Yuerong Shu*1, Yu Zhao*1, Despoina Trasanidou*2, Renee D Hoffman3, Nikolaos Trasanidis4, Michael Zawrotny1, Mary K Gelasco3, Megan
L Medina3, Anuska Das1, Jay Rai1, Hemant N Goswami1, Bing Wang1, John van der Oost2, Hong Li1,3
1Florida State University , Institute of Molecular Biophysics, Tallahassee , FL, 2Wageningen University, Laboratory of Microbiology, Department of Agrotechnology and Food Sciences, Wageningen , Netherlands, 3Florida State University , Department of Chemistry and Biochemistry, Tallahassee, FL, 4 Imperial College London, Department of Immunology and Inflammation, London, United Kingdom
Abstract:
DNA epigenetics play a tremendous role in various aspects of cell biology and human diseases. It is well known that methylation of cytosine, also known as 5mCpG DNA methylation, is the most common form of epigenetic maintenance in mammalian and plant cells. The ability to utilize cytosine methylation as a selective marker both in vitro and in vivo would allow for a more specific approach to utilizing CRISPR-Cas9 for genomic applications. Here we report biochemical, structural, and human genome editing characterizations of a methylation-sensitive type II-C Cas9. The nuclease activity of this Cas9 effector is significantly inhibited by a specific 5mCpG marker associated with the DNA target, while its unmethylated counterpart enables cleavage. We describe highresolution cryo-EM structures of the Cas9 that reveal the molecular basis
for its methylation sensitivity. We further demonstrate the methylation-sensitive editing of this Cas9 within two human cell lines that differ in DNA methylation landscape at the selected targets, paving the way for disease cell-specific editing. The discovery and characterization of the methylation-sensitive Cas9 provides the foundation for a novel strategy in epigenetic-based therapeutics.
Mengying He 1 &Ningjing Song. Friend 1 &Woanting Tay. Friend 2, &Yibin Wang. Mentor 2,3, &Chen Gao. Mentor 1.
University of Cincinnati, Department of Pharmacology and Systems Physiology, Cincinnati,OH 1,
Signature Research Program in Cardiovascular and Metabolic Diseases, DukeNUS Medical School, Singapore 2,
Department of Medicine, Duke University School of Medicine, Durham, North Carolina 3.
Introduction
Alternative mRNA splicing affects a broad spectrum of cardiac genes in heart diseases. Our lab previously identified a muscle-specific isoform of RBFox1 to be a key RNA splicing regulator in pressure overload induced heart failure through regulating Mef2c alternative splicing (AS). However, the physiological impact of RBFox1 in myocardial infarction (MI), and downstream mRNA AS events during MI induced cardiac remodeling remain unknown.
Hypothesis
RBFox1 may play a protective role in MI and hypoxia by mediating splicing variants switch.
Method and Results
To investigate the functional impact of RBFox1 in MI, we utilized AAV9 to achieve cardiac specific expression of RBFox1 in rats. Expression of RBFox1 prevented cardiac dysfunction post MI characterized by improved cardiac function, reduced hypertrophy as well as fibrotic remodeling. In vitro, expression of RBFox1 is sufficient to prevent hypoxia-induced cardiac cell death. In addition, we have identified Mbnl1 mRNA AS regulated by RBFox1 through promoting switch from Long-isoform(L-Mbnl1) to a Short-isoform(S-Mbnl1) lacking 36nt exon7 in C-terminal region. L-Mbnl1 mRNA is sharply increased in cardiac stress conditions including MI and hypoxia. Anti-sense Oligonucleotide (ASO) mediated L-Mbnl1 mRNA inactivation could attenuate cell death under hypoxia and preserve cardiac function post MI. Expression of L-Mbnl1 protein induced more cell death under hypoxia as comparing to S-Mbnl1 in cultured cardiomyocytes. Co-immunoprecipitation assay suggested dramatically altered protein-binding pattern between S-Mbnl1 and L-Mbnl1 variants.
Conclusion
In summary, we have identified the previously uncharacterized role of RBFox1 in myocardial infarction through regulation of Mbnl1 alternative splicing.
Pavel Banerjee1, Sujay Ray1, Liuhan Dai1, Tanmay Chatterjee1, Erin Sandford2, Shankar Mandal1, Muneesh Tewari2, Nils G. Walter1.
1 Department of Chemistry, University of Michigan, Ann Arbor, MI, USA.
2 Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Abstract:
Advanced molecular diagnostics have revolutionized biomarker detection, facilitating early diagnosis and personalized treatments for complex diseases. Particularly, simultaneous multiplexed detection of diverse key biomarkers—such as microRNAs, proteins, and mutant DNAs in body fluids—can transform clinical evaluation by offering synergistic information. However, challenges like cross-reactivity and the detection of low-abundance targets have hindered practical applications in multiplexed settings. To overcome these obstacles, we present Biomarker Single-molecule Chromato-kinetic multi-Omics Profiling and Enumeration (Bio-SCOPE), a triple-modality, simultaneous, multiplexed detection strategy combining chromatic and kinetic fingerprinting through digital encoding. Bio-SCOPE offers femtomolar sensitivity, single-base mismatch specificity, and minimal matrix interference, enabling quantitative digital detection of up to six biomarkers in a single sample with single-molecule sensitivity. Empirical studies highlight the assay’s ability to detect low-abundance targets in the presence of high-abundance ones and quantitatively map multiple microRNAs across various human tissues. Moving Bio-SCOPE towards clinical use, we observed upregulation of specific microRNAs (hsa-miR-141 and hsa-miR-375) in prostate cancer patient samples while simultaneously monitoring other unaffected microRNAs. For simultaneous detection of miscellaneous biomarkers, our Bio-SCOPE assay quantified endogenous biomarkers interleukin-6 (IL-6) and hsa-miR-21 in serum, observing their upregulation in in cytokine release syndrome (CRS) patients compared to healthy individuals. By integrating synergistic pathological cues on a unified, parallelized platform, Bio-SCOPE advances robust multiplexed single-molecule detection of biomarker panels, with transformative potential for precision medicine.
Martin Requena1, Kashish Goe1,l2, Kristopher Brannan1
Center for RNA Therapeutics, Houston Methodist Research Institute1 and Rice University Systems, Synthetic, and Physical Biology Program, Department of Bioengineering2, Houston, Texas 77030, USA
Abstract:
Engineered circular RNAs (circRNAs) are a promising class of nucleic acid therapeutics with potentially higher stability and protein expression compared to linear mRNA equivalents. Lacking a 5’ terminus, circRNAs typically use Internal Ribosomal Entry Sites (IRESes) instead of a 5’ m7G cap for ribosomal recruitment. This allows them to be switched off using RNA ‘triggers’ that disrupt IRES function by hybridizing with engineered ‘toeholds’ that are engineered into key portions of the IRES secondary structure, allowing for conditional activation or suppression of translation based on the presence of endogenous mRNA sequences, including disease-associated mRNAs. Screens for optimizing IRES toeholds can be labor-intensive, requiring in vitro transcription, circularization, and transfection of each construct. Circ G//FP – our split GFP circRNA system for single-cell screening of IRES activity and circularization of circRNAs produced directly in cellulo – could enable greater sampling of sequence space without having to individually transcribe and circularize each circRNA construct. We also present G\\FP re:verse, a version of circ G//FP capable of functioning as a Boolean NOT gate when paired with a tet-On reporter plasmid. Our system replicates in vitro results of IRES translational efficiency in cellulo, facilitating more efficient screening of IRES variants and potentially other components of circRNAs. We aim to expand this toolkit to include the capacity for stable cell library creation with expression of a single copy per cell to enable more precise screening, screening of IRES toeholds, and error-prone PCR screens to discover and refine novel IRES designs for therapeutic applications.
Yu Zhao1, Jay Rai1, Lauren Cohen3, Chong Xu2, Hemant Goswami1, Virginie Marchand4,
Yuri Motorin5, Homa Ghalei3 and Hong Li1,2
Institute of Molecular Biophysics1, Department of Chemistry and Biochemistry2, Florida State University, Tallahassee, FL 32306, USA.
Department of Biochemistry, Emory University School of Medicine3, Atlanta, GA 30322, USA.
Université de Lorraine, EpiRNA-Seq Core Facility, UAR2008/US40 IBSLor4, CNRS-Inserm,
F-54000 Nancy, France.
Université de Lorraine, IMoPA, UMR7365, CNRS5, F-54000 Nancy, France.
Abstract:
Eukaryotic ribosomal RNAs contain abundant post-transcriptional modifications installed by
snoRNPs that are often regulated during disease development. Though the modifications are known to modulate chemical and thermodynamic properties of model RNA fragments, their impact on the megadalton ribosome complexes during translation and along the maturation pathways remains elusive. We obtained a series of cryoEM structures of both the ribosomes and their maturation complexes that lack 2’-O-methylation and discovered previously unappreciated roles of this modification. Methylation loss significantly reduces the thermostability and structural integrity of the ribosome but interestingly, increases the rate of in vitro translation. During ribosome biogenesis, we observed a role of methylation in maintaining the orderly RNA folding, especially at the domain junctions and the peptidyltransferase center, and binding of assembly factors. The absence of the modification accumulates off-path maturation intermediates and, in some cases, transient assembly chaperons, thereby significantly reducing the number of mature ribosomes. Our data provide a framework to understand the roles of the snoRNP-installed modifications in regulation of translation. They also provide structural basis for the genetic diseases linked to hypomodifications, such as dyskeratosis congenita or certain types of acute myelogenous leukemia.
Laura Vallance1, Fatemeh Fattahi1, Jason S. Ellis1, Kristin Bahleda2, Julia Holden1, Sarah Socha1, Francisco Gomez-Rivera1, Ulus Atasoy1,3
1- Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI
2- Boston’s Children’s Hospital, Boston, MA
3- Division of Allergy-Immunology, Ann Arbor VA Health System, Ann Arbor, MI
Abstract:
RNA-binding protein HuR (Elavl1) plays a critical role in T cell activation and immune response by regulating mRNA stability and transport. To investigate HuR’s role in regulatory T cell (Treg) function, we generated the Foxp3YFP/Cre HuRfl/fl mouse, where HuR is selectively deleted in Tregs, essential for immune homeostasis and self-tolerance. Homozygous and hemizygous Foxp3YFP/Cre HuR fl/fl mice developed a scurfy-like phenotype, including failure to thrive, splenomegaly, hair loss, tail stippling, and widespread multiorgan immune cell infiltration. Molecular analysis revealed that HuR directly interacts with Foxp3 mRNA, promoting its stability and Treg function. Loss of HuR led to decreased Foxp3 expression both in thymus and periphery, reduced Foxp3 mRNA stability and impaired Treg suppressive capacity. To further investigate the molecular consequences of HuR deletion, we performed RNA sequencing (RNA-Seq) on YFP+ Tregs from HuR KO mice. Ingenuity Pathway Analysis (IPA) of RNA-Seq data revealed significant dysregulation of several pathways, including the T helper differentiation pathway, in which Foxp3 plays a central role. Protein-Protein Interaction (PPI) analysis confirmed a direct link between FOXP3 and RORC (encoding RORγt), which connects FOXP3 to the T cell differentiation pathway via IL-23R. These genes were downregulated in both RNA-Seq and qPCR analyses. Our study demonstrates that HuR ablation in Tregs disrupts Foxp3 expression and key molecules involved in T cell differentiation pathways, including RORC, potentially contributing to a disrupted Treg-Th17 axis and autoimmune dysfunction. This underscores the critical role of HuR in post-transcriptionally regulating Foxp3, which is essential for maintaining immune homeostasis and preventing autoimmunity.
Julia Haas 1, Johann Roque 1, Beth Anderson 1, Ariel Thelander 1, Will Ford 2, Aparajita Chakraborty 3, Paul Robustelli 3, Blanton Tolbert 2, and Brittany Morgan 1.
University of Notre Dame, Department of Chemistry & Biochemistry 1, University of Pennsylvania, Department of Biochemistry & Biophysics 2, and Dartmouth College, Department of Biochemistry and Cell Biology 3.
Abstract:
RNA Binding Proteins (RBPs) control many cellular processes including transcription, translation, and alternative splicing. RBPs have the most disease annotated mutations of any protein class, but these proteins have historically been considered “unligandable” due to their i) highly dynamic and disordered nature and ii) high level of conservation within their RNA binding domains (RBDs). We hypothesized that differences in protein dynamics could be exploited to enable covalent ligands to selectively target conserved cysteines within RBDs. To investigate this, we screened a library of cysteine-reactive covalent ligands against homologous RBPs with differences in their protein dynamics: heterogeneous nuclear ribonucleoproteins H and F (hnRNP H and F). hnRNPs H and F are an excellent model system for RBP conservation because they have over 89% sequence similarity, three parallel quasi-RNA recognition motifs (qRRMS), and three conserved cysteines (C22, C34, & C122) within their RBDs. Despite this conservation, we observed differences in the covalent labeling of hnRNP H and F during in vitro screenings. Notably, we found one small molecule with a ten-fold difference in selectivity for hnRNP H over hnRNP F and we consistently observed greater covalent labeling of cysteines in hnRNP H. This work demonstrates that covalent ligands can be used to differentially engage conserved cysteines. Moreover, our findings suggest that the unique dynamics of hnRNP H, specifically slower conformational exchange, may contribute to greater covalent labeling. By understanding how protein dynamics contribute to covalent selectivity, we can cultivate a powerful new approach for targeting RBPs and other dynamic and disordered proteins.
Vrutant Shah1, Maria F. Chervo2, Aravind Sundaravadivelu1, Jenny C. Chang2, Kristopher W. Brannan1
Center for RNA Therapeutics, Department of Cardiovascular Sciences1 and Cancer Center2, Houston Methodist Research Institute, Houston, TX 77030, USA
Abstract:
Metaplastic breast cancer (MpBC) is a rare and aggressive subtype of triple-negative breast cancer (TNBC) with a worse prognosis and poorer patient survival. MpBC is chemoresistant and lacks druggable targets, necessitating new therapeutic approaches. At the molecular level, the PI3K/AKT pathway is hyperactivated, and a gain-of-function mutation in ribosomal protein L39 (RPL39) contributes to treatment resistance, stem cell self-renewal, and lung metastasis. RPL39 increases inducible nitric oxide synthase (iNOS)-mediated NO production, which is linked to poor patient survival in MpBC.
RPL39, an RNA-binding protein, may alter the translational landscape specific to MpBC. We hypothesize that RPL39-mediated signaling leads to the altered translation of specific genes and transcript isoforms, promoting invasive metaplastic tumors. Our lab has shown that by fusing APOBEC1, an RNA editing enzyme, to an RNA-binding protein (RBP), we can identify RNA edits at RBP-RNA interaction sites via RNA-Seq. We have established TNBC and MpBC cell lines with RPL39-APOBEC fusion to determine the translational landscape and gene expression.
Additionally, we have created RPS2-APOBEC patient-derived xenografts (PDXs) from TNBC and MpBC patients and performed single-cell RNA-Seq to analyze the translational and transcriptomic landscape in heterogeneous tumor samples. After identifying genes overexpressed in MpBC, we will validate their roles through functional assays. ADAR1, another RNA editing enzyme, is overexpressed in TNBC and MpBC. We are designing and evaluating ADAR1-based RNA sensors using validated gene targets. This study aims to elucidate the molecular regulation of RPL39 in MpBC at both the transcript and protein levels, with potential therapeutic targets for drug discovery or RNA sensor design.
Jeffrey Clancy, Haixiang Yu, George Pitoc, Bruce Sullenger
Department of Surgery, Duke University, Durham NC 27710
Abstract:
Efforts to reduce large animal farming and substitute red meat with more sustainable dietary alternatives are increasingly recognized strategies to curb greenhouse gas (GHG) emissions. However, the need to replace other large animal-derived products is often overlooked. Production of unfractionated heparin (UFH), a World Health Organization (WHO)-designated essential medicine, critical for cardiac surgery and many other clinical applications, relies on the farming of over a billion large animals annually. To date, insufficient potency and limited reversibility have hindered the development of a synthetic UFH replacement. We present HD1-12dmA-DAB, an aptamer-based potent and rapidly reversible synthetic anticoagulant created by conjugating a thrombin exosite-binding aptamer, HD1, with a thrombin active-site inhibitor, dabigatran. By incorporating synergistic EXosite and ACTive site binding to create what we terms as an EXACT inhibitor, both the thrombin binding affinity and specificity of HD1-12dmA-DAB is improved by orders of magnitude compared to the aptamer and dabigatran alone. HD1-12dmA-DAB demonstrates UFH-comparable anticoagulant activity in in vitro, in vivo, and ex vivo clotting models, making it one of the most potent anticoagulants known to date. Additionally, its nucleic acid basis makes HD1-12dmA-DAB’s effect reversible with a complementary oligonucleotide, an attribute critical for many surgical and clinical applications. Our findings provide the foundation for the development of a more sustainable UFH alternative with the potential to effectively treat millions of patients while reducing GHG emissions. It also provides an effective strategy to develop potent and reversible nucleic acid-based EXACT inhibitors against numerous proteases that are important targets in different diseases.
Alli Jimenez1, Bryan B. Guzmán2, Daniel Dominguez1,2
Departments of Biochemistry & Biophysics1 and Pharmacology2, University of North Carolina at Chapel Hill, Chapel Hill, NC
Abstract:
RNA binding proteins (RBPs) bind to RNA at various levels of transcriptional processing and can therefore be thought of as master regulators of gene expression. RBPs typically interact to short RNA motifs through well-folded RNA-binding domains (RBDs). However, RBPs are also enriched for segments of disorder which often contain RGG/RS amino acid repeats, termed low-complexity domains (LCDs). Previous work from our group has shown that a wide range of RBP LCDs can interact with specificity to RNA G-quadruplexes (rG4s). rG4s are highly stable four-stranded RNA structures that form through Hoogsteen and pi-pi stacking interactions. Here we investigate RNA-target selectivity through the prototypical RBP, HNRNPR, which contains three RNA recognition motifs (RRMs) and a C-terminal glycine-rich low complexity domain (LCD). We used an unbiased protein-RNA binding assay, RNA-bind-n-seq (RBNS), to determine HNRNPR’s preferred RNA motifs against a random pool of RNA oligonucleotides. While our results show an overall preference towards AU-rich sequences, the LCD prefers G-rich sequences. We further validated and investigated the LCD-rG4 interaction through fluorescence polarization (FP) assays and found that arginines in the LCD promote multivalent, high affinity binding to rG4s. Furthermore, we discovered a non-canonical extended RRM domain that is required for binding to AU-rich sequences and surprisingly can also interact to rG4s. Through this work, we provide evidence for the mechanisms by which HNRNPR interacts to RNA and highlight the importance of dissecting multi-RNA binding domains to better understand RBP-RNA interactions.
Angelica Previero, Tevon Madry, Julia D’Arca, Hudson Mizgalski, Gyorgyi Csankovszki.
LSA
Abstract:
Polyploidy is a highly widespread phenomenon, appearing in processes such as evolution, cancer, regeneration, and development, sometimes in all cells which are part of a tissue, while other times in only a subset. However, even though polyploidy is clearly a fundamental phenomenon across life, the gene expression differences between diploid and polyploid cells are not clear. One of the few organisms that can be fully turned tetraploid is the roundworm Caenorhabditis elegans. Tetraploid C. elegans develop more slowly, are less reproductively fit, age faster, and have an overall shorter lifespan. Besides physiological differences, RNAseq data also shows differential gene expression in tetraploid C. elegans with respect to their diploid counterparts. Interestingly, several genes that are both upregulated and downregulated are tissue specific genes involved in tissue specific programs. This data highlights the effects of multiple copies of DNA on specific genes and starts to elucidate why this phenomenon is so conserved across different organisms and stages of life.
SungHee Park, George Maio, Andrew Bond and Li-Tao Guo
RNAConnect Inc., Branford, Connecticut 06405
Abstract:
Reverse transcription combined with template switching reactions offers a robust, streamlined approach to produce full-length cDNA libraries and conduct adapter ligation in RNA-Seq workflows. Many RNAs of increasing interest are long and structurally complex, including those involved in development, environmental stressors, regulatory pathways, and responses to disease. However, quantitative full-length cDNA synthesis with traditional Moloney murine leukemia virus (MMLV) reverse transcriptases (RTs) can be challenging due to their inherently low processivity. A single stable RNA structure element is enough to stall MMLV RTs, which can reduce or eliminate the presence of target RNAs in final libraries, thus limiting our ability to accurately profile transcriptomes.
The introduction of UltraMarathonRT® (uMRT), an ultra-processive RT capable of maintaining high fidelity across all RNAs including long, structured sequences, has resolved these challenges. Here, we detail uMRT’s role in RNA-seq library preparation for quantitative transcriptomic profiling and compare it with MMLV-based methods using well-characterized RNA reference sets of synthetic spike-in standards, human and plant RNA samples. We found that, using human total RNA, uMRT captures 10,000 more genes, such as the ultra-long HERC1 and XIST RNAs, that are undetected by Smart-seq2 using a highly optimized MMLV RT. Using RT-qPCR, we subsequently validated that the sequencing reads generated with uMRT more accurately capture RNA identity and abundance across a six-log range of transcript concentrations. This improved sensitivity and accuracy are critical for complex transcriptomic research, as they allow for the detection of rare transcripts and enhanced representation of full-length mRNAs.
Henry C Arthur1, Mason T Myers1, Renke Tan1, Yan Zhang1
1 Department of Biological Chemistry, University of Michigan, Ann Arbor, MI
Abstract:
Type I CRISPR-Cas phage defense systems are widespread in prokaryotes. They target the viral genome in an RNA-guided fashion, using a multi-subunit DNA binding complex called Cascade and a helicase-nuclease fusion factor Cas3 that degrades large DNA stretches.[1] In 2019, we pioneered the use of Type I CRISPR for Kb-to-Mb sized deletions in the human genome.[2] The Type I CRISPR toolkit has greatly expanded ever since to include transcriptional activation, DNA integration, and base editing tools, all of which rely on guide RNAs encoded on a plasmid or as chemically modified linear RNA. There are currently no circular guide RNAs (circRNA) developed for Type I gene editing, hindering the clinical translation of these promising technologies. Compared to linear RNAs, circRNAs may lower immunogenic risk and improve editing efficiency through their longer half-life in cells. Recently, circular pegRNA has been shown to effectively support split-Cas9-prime editors in human cells.[3],[4] Here we develop a robust strategy using self-cleaving ribozymes to produce in vitro circRNAs for the Type I-C CRISPR-Cas3 gene editor. We electroporated these circRNA along with mRNAs encoding Nla I-C cas genes into HEK293T-GFP reporter cells. While a linear in vitro transcribed guide RNA only elicited <5% GFP targeting, our circRNA enabled GFP disruption up to 80%. This high efficiency is on par with results obtained using a chemically modified linear synthetic guide. Our findings encourage future optimization efforts towards a Type I CRISPR circRNA and pave the way for their in vivo and therapeutic applications.
Somnath Mahapatra1,2*, Fengyun Su1,2, Xuhong Cao1,2, Christine Caldwell Smith1,2, Rui Wang1,2, Gabriel Cruz1,2, Radha Paturu1,2, Kayla Muschong1,2, Dan Robinson1,2, Yi-Mi Wu1,2, Hanbyul Cho1,3, Rupam Bhattacharya1,2, Saravana Dhanasekaran1,2, Rohit Mehra1,2, Yuping Zhang1,2, Rahul Mannan1,2, Arul M Chinnaiyan1,2,4,5
1. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI
2. Department of Pathology, University of Michigan, Ann Arbor, MI
3. Department of Bioinformatics, University of Michigan, Ann Arbor, MI
4. Department of Urology, University of Michigan, Ann Arbor, MI
5. Howard Hughes Medical Institute, Ann Arbor, MI
Introduction
Formalin-fixed paraffin-embedded (FFPE) tissue archives represent the largest source of clinical specimens with well-preserved histomorphology making them invaluable resource for spatial transcriptomics (ST). However, RNA integrity assessment in FFPE tissues remain a significant challenge, with current metrics like DV200 (estimated at bulk level) often failing to reliably predict RNA integrity within specific regions of interest (ROI). Here we present an integrated approach combining DV200, RNA in-situ hybridization (RNA-ISH), and pre-library PCR matrices to enhance RNA quality assessment in FFPE tissues.
Design
We analyzed 20 FFPE tissue specimens, predominantly prostatic adenocarcinomas with varying Gleason grades, using the Visium-HD Cytassist platform. RNA quality was assessed using DV200 quantification, chromogenic RNA-ISH targeting Peptidylprolyl Isomerase B (PPIB), and pre-library RNA measurements. Correlations between these metrics and mean unique molecular identifier (UMI) values from ST sequencing were evaluated, using vendor-recommended thresholds of 100 for mean UMI and 30 for DV200 scores.
Results
PPIB RNA-ISH expression correlated significantly (p<0.01) with mean UMI values. DV200 identified 14/15 libraries with sufficient mean UMI but detected only 1/5 low-UMI libraries. By integrating DV200 and PPIB metrics, we achieved superior performance, successfully identifying 4/5 low-UMI libraries, achieving an impressive 93% sensitivity and 80% specificity.
Conclusion
Our study demonstrates that combining DV200 and PPIB expression metrics provides a robust, data-driven framework for RNA quality assessment in ST analysis of FFPE tissues. This integrated approach ensures reliable tissue evaluation, advancing spatial transcriptomics and its applications in clinical research.
Jacob Horn, Rachel Niederer
Cellular and Molecular Biology; Department of Biological Chemistry
Abstract:
SARS-CoV-2 protein Nsp1 induces a global translation shutdown in host cells upon infection. The viral genome can escape the translational shutdown via secondary structure in its 5’ untranslated region (UTR). The first hairpin structure, stem-loop 1 (SL1), has been identified as necessary and sufficient to evade Nsp1-mediated translation shutdown. Despite proven functional roles within the 5’ UTR, other elements remain understudied. We wondered if the 5’ UTR has other functional regions that might influence translational control and evasion of the translational shutdown. We will use a recently developed method called direct analysis of ribosome targeting (DART), a high throughput method that tests the ribosome recruitment ability of thousands of 5’ UTRs. We generated a diverse pool of sequences that will allow thorough examination of each region of the 5’ UTR and its role in translation and evasion of host shutdown. The pool includes all known natural mutations, along with artificial scanning, structural disrupting and compensatory mutations. Completing DART with and without Nsp1 will elucidate what elements facilitate translation and the evasion of Nsp1-mediated translational shutdown.
Alice M. Youle* and Rachel O. Niederer
Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Abstract:
The 5′ untranslated region (UTR) of an mRNA is a critical feature in regulating translational output. Several features within the 5′UTR are known to affect translation, including secondary structure and upstream start codons. Secondary structure is often repressive of translation initiation by impeding scanning of the ribosome or recruiting regulatory RNA-binding proteins. Secondary structure also likely affects the recognition and efficiency of other features, such as upstream start codons (uAUGs), which are also commonly repressive of translation. However, the interplay of these regulatory elements within 5′ UTR, and their combined impact on translational output requires further characterization. An intriguing example of a 5′ UTR which contains both secondary structure and upstream start codons is CFTR, the causative gene of cystic fibrosis. Through mutational analysis and in vitro translation assays, we identified that secondary structure within the 5′ UTR suppresses translation of CFTR particularly when located at the 5′ end of the mRNA, and that shifting the structure downstream by only 4 nucleotides is sufficient to promote translation. Surprisingly, we also find that the uAUG is not inhibitory for translation of CFTR as expected, but rather enhances translational output. Further, we find evidence that translation initiation may be occurring at a noncanonical upstream start site in addition to the uAUG and main start codon. These findings establish the CFTR 5′ UTR as an interesting model for uncovering mechanistic details of RNA translation regulation, as well as a potential therapeutic target to increase CFTR expression in CF patients.
Junzhe Guo12, Lydia Freddolino13* and Chengxin Zhang13*
Department of Computational Medicine and Bioinformatics1, University of Michigan, Ann Arbor, MI,
48109, USA
Current address: Department of Biochemistry and Molecular Pharmacology2, Baylor College of
Medicine, Houston, TX, 77030, USA
Department of Biological Chemistry3, University of Michigan, Ann Arbor, MI, 48109, USA
Abstract:
Experimental RNA structures determined by X-ray crystallography or cryo-EM frequently contain nucleotide residues whose coordinates cannot be determined, posing challenges for biological interpretation and structure-based function analysis. Current RNA loop modeling programs (e.g., PDBFixer and ModeRNA) used to reconstruct these missing nucleotides suffer from long running times and low accuracies. To address these issues, we developed Full-atomic Loop modeling Of RNA (FLORA), a novel loop modeling pipeline to reconstruct full-length RNA structures from the full nucleotide sequence and an incomplete 3D structure of the input RNA. To achieve this, FLORA utilizes several sub-methods to initialize candidate loop conformations using secondary structure constraints detected from the input structure and predicted from the full-length sequence. The initial loop conformations are then iteratively refinement by a deterministic simulation process to correct bond lengths, bond angles, clashes, base planarity and chirality, and a ranking procedure used to select a final model. On a large dataset of 4931 loops from 591 experimental RNA structures, FLORA achieves a mean RMSD of 12.7 Å, which is 29% and 40% lower than ModeRNA and PDBFixer, respectively. FLORA is available at https://github.com/kad-ecoli/FLORA, and via a webserver hosted at https://seq2fun.dcmb.med.umich.edu/FLORA/.
Matthew H. Hall (1,2,3), Peter Y. Wang(1,2,3), Thy Pham (1,2,3), David Bartel (1,2,3)
1: Howard Hughes Medical Institute, 2: Massachussetts Institute of Technology, 3: Whitehead Institute for Biomedical Research, Cambridge, USA
Abstract:
MicroRNAs (miRNAs) associate with Argonaute (AGO) proteins and serve as guides, directing those AGO proteins to sites of partial sequence complementarity in the 3ʹ-UTRs of mRNAs. Binding of the AGO–miRNA complex to the target site results ultimately in decay of the target mRNA, with the magnitude of this post-transcriptional repression determined by the binding affinity. For a target site to achieve sufficient affinity to impart meaningful repression, base pairing to the miRNA seed region (nucleotides 2–8) is typically necessary and sufficient.
Here we report an investigation of unusual target sites with extensive complementarity to the miRNA 3ʹ-region (nucleotide 9 onwards) but without seed pairing. The best of these “3ʹ-only” sites bind as well as top canonical sites and impart similar repression, which can be further boosted by as few as 2–3 additional base pairs to the miRNA seed. However, 3ʹ-only sites have significantly slower association and dissociation rates than seed sites, and individual miRNAs differ with respect to how well they bind their respective 3ʹ-only sites. Moreover, chemical probing of miRNA backbone accessibility suggests different conformations for AGO–miRs bound to 3ʹ-only versus canonical sites. Drawing on these results, we propose a seed-independent mechanism of AGO–miR engagement with 3ʹ-only sites which involves release of the miRNA 3ʹ-end from the PAZ domain of AGO. We estimate that for miRNAs that recognize 3ʹ-only sites, these sites constitute 0.5–1% of the endogenous targetome, a similar proportion to other rare but important site types such as 3ʹ-compensatory sites.
Elena Alvarez-Periel1, Marianne C. Kramer2,3, Cagla Akay-Espinoza1, Daniel P. Jackson1, Julia A. Tasca4, Benjamin A. Garcia4, Brian D. Gregory2,3, Kelly L. Jordan-Sciutto1
1 Department of Oral Medicine, School of Dental Medicine, 2 Department of Biology, 3 Cell and Molecular Biology Graduate Group, 4 Epigenetics Institute, Department of Biochemistry and Biophysics; University of Pennsylvania, Philadelphia, PA, 19104
Abstract:
RNA regulation by RNA-binding proteins (RBPs) plays a particularly relevant role in neurons and in cellular responses to stressors. One important neuronal stressor is excitotoxicity, which is associated with activation of NMDA receptors. Both excitotoxicity and aberrant function of RBPs are prevalent hallmarks in multiple neurodegenerative disorders. However, global analysis of RNA structure and RNA-protein interactions in primary neurons in response to excitotoxicity has not been assessed. To this end, we have performed protein interaction profile sequencing (PIP-seq) in primary neurons treated with NMDA to induce excitotoxicity. We observe that NMDA treatment significantly alters RNA secondary structure around the start and stop codons, and that reduction of RNA structure at the 3’UTR correlates with increased mRNA abundance as assessed by mRNA-Seq. Total RNA-protein binding sites increase in response to excitotoxicity and, interestingly, different RNA-protein binding locations in this context defines subsets of transcripts functionally associated with synaptic functions and neurodegenerative disorders. We further identify two RNA motifs enriched in protein binding in the context of excitotoxicity and a list of proteins binding to them in vitro. Finally, we observe that two of these RBPs, CELF6 and YBX3 alter their protein levels in response to NMDA treatment, suggesting their involvement in RNA regulation in response to excitotoxicity. Overall, we describe the global landscape of RNA structure and RNA-protein interactions in primary neurons in baseline conditions and in an in vitro model of excitotoxicity, providing insights into the role of RBPs and RNA structure changes in neurological diseases associated with excitotoxicity.
Disha Kashyap1,2, Thomas A. Milne2,*, Michael J. Booth1,3,*
1Department of Chemistry, University of Oxford, Mansfield Road, Oxford, OX1 3TA, U.K.
2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK
3Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, U.K.
*Correspondence: thomas.milne@imm.ox.ac.uk, m.j.booth@ucl.ac.uk
Abstract:
Antisense oligonucleotides (ASOs) are a promising class of therapeutics designed to modulate gene expression. Both key mechanisms of action for ASOs operate in the nucleus: splice-switching ASOs modify pre-mRNA, processed in the nucleus, and mRNA-degrading ASOs require RNase H, an enzyme predominantly active in the nucleus. Therefore, to achieve maximal efficacy, ASOs require efficient nuclear delivery. Current ASO therapeutics shuttle in and out of the nucleus inefficiently. In this work, we have synthesised ASO conjugates for active nuclear import, by covalent conjugation with a potent small-molecule nuclear importer, (+)-JQ1. (+)-JQ1 is a well-characterised high-affinity binder for members of the BET bromodomain family of proteins and was recently shown to transport cytoplasmic proteins into the nucleus. Our (+)-JQ1-ASO conjugates outperformed their unmodified counterparts for both splice-switching and mRNA knockdown in the nucleus, at all concentrations tested. In particular, we improved the performance of Oblimersen, a BCL-2 ASO drug that failed phase-III clinical trials, showing that this therapeutic may merit re-evaluation. This work shows that the covalent modification of ASOs with a small-molecule nuclear importer can significantly improve target engagement and pave the way for more effective therapeutics.
Roque, Johann1*, Haas, Julia A1*., Markey, Chloe E 2*., and Morgan, Brittany S. Mentor 1*
1- Department of Chemistry and Biochemistry, University of Notre Dame Southbend, Indiana 46556, USA
2- Department of Biomedical Engineering, University of Duke, Durham, North Carolina 27708, USA
Abstract:
Dynamic protein loops are essential for a multitude of cellular functions, have been implicated in numerous diseases and have historically proven difficult to target with small molecules. Recently, screening campaigns have led to the serendipitous discovery of covalent small molecules that form selective bonds with dynamic loops leading to an array of covalent probes and drugs; the most prominent example is FDA-approved drugs that covalently target oncoprotein KRAS(G12C). Despite this success, we have limited insight on the biophysical and structural basis of the observed covalent selectivity. The goal of my research is to establish foundational principles for how covalent ligands selectively target dynamic loop regions and leverage these principles toward the rational targeting of these loop regions. In pursuit of these goals, I have utilized covalent ligands to analyze structure-affinity relationships for three unique dynamic loops: 1) transcription factor Med25, 2) heterogenous nuclear ribonucleoprotein H (hnRNP H), and 3) hnRNP F. My efforts have revealed the key role of i) loop dynamics on rate of covalent bond formation; ii) ligand shape in loop specificity; and iii) traditional ligand features, such as polar volume and partial charge, on loop affinity. These first-in-line principles are essential for understanding the biophysical and structural basis of covalent ligand selectivity; and in the future, the generalizability of these principles will be tested with additional dynamic loops, leading to an avenue for the rational design of small molecule that target dynamic and/or disordered protein structures.
A.M. Allouch1,2, S.E. Elzinga1,2, B. Kim1,2, R.E. Henn1,2, M.H. Noureldein1,2, F.E. Mendelson1,2, J.M. Hayes1,2, D.M. Rigan1,2, M.G. Savelieff1,4, J. Hur1,4, K. Guo1,4, Y. Zou3, E. L. Feldman1,2
1. Department of Neurology, University of Michigan, Ann Arbor, 48109, USA
2. NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, 48109, USA
3. Department of Chemical Engineering, University of Michigan, Ann Arbor, 48109, USA
4. Department of Biomedical Sciences, University of North Dakota, Grand Forks, 58203, USA
Obesity, prediabetes, and diabetes induce adipose tissue inflammation, contributing to diabetic complications, including those of the central nervous system (CNS). Adipose tissue inflammation increases production of adipose tissue-derived extracellular vesicles (ATEVs), which can cross the blood-brain barrier and may promote CNS inflammation. However, inflammatory mechanisms underlying this potential adipose-microglia crosstalk are unclear. As microRNAs (miRNAs) are suggested mediators of peripheral and CNS inflammation, our goal was to assess the effect of obesity/prediabetes on the miRNA content of ATEVs and inflammatory gene expression profiles of microglia. 5-week-old male C57BL/6 mice were fed standard diet (SD) or high-fat diet (HFD) for 1 or 3 months to induce obesity/prediabetes. ATEVs were isolated from white epididymal adipose tissue, and their size and concentration measured using Nanoparticle Tracking Analysis. ATEV miRNA content was analyzed via NanoString nCounter, and single-cell RNA sequencing data from hippocampal microglia used to understand correlations between ATEV miRNAs and microglial inflammatory gene expression. ATEVs were also used to treat a human microglial cell line to assess microglia uptake of ATEVs and inflammatory gene expression after treatment. Obesity reduced ATEV miRNAs which regulate NF-κB pathway genes and correlate with NF-κB activation. HFD increased ATEV production, and ATEVs elevated NF-κB expression in microglia. let-7f and miR-141 mimics reduced expression of IKK-⍺, a key regulator of the NF-κB pathway, in palmitate-treated microglia. Collectively, our perliminary data indicate that HFD reduces expression of ATEV miRNAs that regulate the NF-κB pathway. This implicates adipose-microglia crosstalk as a mechanism contributing to peripheral to CNS inflammatory spread.
Rajat Mudgal1, Dishari Thornhill1, Kai-Neng Chou1, Akira Ono1
1Dept. of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI
Abstract:
HIV-1 continues to cause mortality and morbidity to people living with HIV despite effective antiretrovirals. A multifunctional viral structural protein Gag drives HIV-1 particle formation at the plasma membrane. Matrix (MA) and nucleocapsid (NC) are two major Gag domains that bind RNA during HIV-1 particle assembly. RNA binding to MA highly basic region (MA-HBR) is hypothesized to prevent premature or promiscuous membrane binding of Gag. The vast majority of MA-bound RNAs in cells are tRNAs, but the details of Gag-tRNA binding remain to be determined.
In the current study, we applied modified photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation (PAR-CLIP) approaches to an NC-deficient Gag variant (delNC) and full-length Gag. We found that most tRNAs that bind to membrane-binding-incompetent (MBI) version of delNC Gag were those present abundantly in the cytosol. However, selenocysteine tRNA (SeCTCA), a less abundant tRNA, was over-represented in the MBI delNC Gag-bound tRNAs. Importantly, the tRNAs bound less to membrane-binding-competent delNC Gag than to MBI delNC Gag, suggesting mutual exclusivity between Gag-membrane and Gag-tRNA binding. In the context of full-length Gag, SeCTCA binds only MA-HBR, while other tRNAs bind both MA-HBR and NC. Preliminary data showed that overexpression of SeCTCA in a T cell line significantly decreased HIV release, suggesting a physiological role of SeCTCA in HIV-1 life cycle. Ongoing studies are aimed at elucidating the mechanism by which SeCTCA inhibits HIV-1 particle release and identifying the interaction interphase between SeCTCA and MA-HBR, which can be exploited as a potential target of novel RNA-based antiviral therapeutic strategies.
Tehreem Fatima
RNA Institute, University of Albany,
Cognitive Science Institue, University of Connecticut
Abstract:
Myotonic dystrophy type 1 (DM1) is a complex genetic multisystemic disorder marked by the expansion of CTG repeats within the 3′ untranslated region of the dystrophia myotonic protein kinase (DMPK) gene. DM1 is associated with a severe neuromuscular phenotype, encompassing early-onset ataxia, dysarthria, muscle weakness, and exercise intolerance. The sophisticated nature of DM1 necessitates a nuanced exploration of its molecular groundworks. In this study, I embarked on an investigation into the potential roles of long non-coding RNAs (lncRNAs) in DM1 pathophysiology. LncRNAs, once regarded as genomic “junk,” have emerged as critical regulators of gene expression and alternative splicing, making them intriguing candidates for understanding DM1’s underlying mechanisms. Within the realm of alternative splicing in DM1, I identified NUTM2A-AS1 as a potential player, substantially influencing splicing patterns in DM1-affected brains. Importantly, this lncRNA exhibited non-coding repeat expansions, suggesting a central role in the development of DM1.
Additionally, I unveiled other lncRNAs with their associated genes and proteins, such as KHDRBS3 and HDAC2, each offering unique insights into the complex world of alternative splicing. Regarding differential gene expression in DM1, I pinpointed several lncRNAs and their corresponding genes or proteins, including MAP6, FOSL2, and HLA-DQB1. These discoveries illuminate the intricate interplay of genes and proteins, shedding light on the multifaceted nature of DM1.
Eric W. Ji (1), Evrim Yildirim (1), Peter K. Todd (1,2)
Department of Neurology (1) and Veterans Affairs Medical Center (2), University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Abstract:
Nucleotide repeat expansion disorders are characterized by long sequences of repeat nucleotides that contribute to toxic protein accumulation and disease pathology. In particular, amyotrophic lateral sclerosis (ALS) and fragile X-associated tremor/ataxia syndrome (FXTAS) are neurodegenerative disorders caused by a hexanucleotide G4C2 repeat in the C9orf72 gene and a CGG repeat in the 5’UTR of the FMR1 gene, respectively. These repeats induce neurodegeneration as RNA by interacting with and sequestering RNA binding proteins while also triggering repeat-associated non-AUG initiated (RAN) translation of toxic peptides. To better understand how these repeats induce neurodegeneration, we used Drosophila melanogaster models for ALS and FXTAS where we expressed G4C2 and CGG repeats in master pacemaker neurons. PDF cell expression triggered accumulation of RAN translated peptides in these neurons and an age-dependent loss of circadian rhythmicity. We took advantage of the extensive genetic variance among the fully sequenced inbred lines of Drosophila Genetic Reference Panel (DGRP) to identify potential genetic modifiers of G4C2 and CGG repeat toxicity. For both experimental groups, expression of the repeat in pacemakers of DGRP lines decreased the circadian rhythm strength with a different extent in each line. We conducted a genome wide association study (GWAS) to identify genes responsible for the differential response to the challenge associated with these repeats. Our GWAS analysis found several notable genetic modifiers of interest for both repeats. Further research will explore these specific genes to better understand disease mechanisms and potential therapeutic approaches for ALS and FXTAS.
Kaley M. Simcox, Robert T. Kennedy, and Kristin S. Koutmou
Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA
Abstract:
Transfer RNAs (tRNAs) are the most abundantly modified RNA class with around 20% of all nucleotides containing a chemical modification installed by the cell. These modifications are essential for the proper structure and function of tRNAs. Particularly modifications on the tRNA body are responsible for proper tRNA folding and stability, whereas modifications in the anticodon stem-loop play a role in translation. While the importance of tRNA modifications is largely understood, the location of tRNA modification for many organisms remains unknown. Therefore, rigorous methods are needed to map modifications onto their respective tRNA confidently. Liquid chromatography coupled to tandem mass spectrometry has enabled the direct sequencing of tRNA modifications by confidently identifying modifications by their corresponding masses. Traditionally, sequence coverages have been limited by the specificity and availability of RNase enzymes. RNase T1 (G specific) and RNase A (pyrimidine specific) are the most widely used because other enzymes (e.g. cusativin and MC1) cleave endogenous RNAs which makes attaining sufficient enzyme yields challenging. To avoid these limitations, our lab has previously improved sequence coverage of S. cerevisiae tRNA through orthogonal digestions using RNase T1 and RNase A while the tRNA is folded in the presence of magnesium. Here, I have incorporated RNase IV into the LC-MS/MS tRNA sequencing pipeline to further increase the sequence coverages of purified E. coli tRNAs.
Marla Gravino, Adam Wier, Adam Albritton
Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, USA
RNA is widely recognized for its role as a messenger in the central dogma. However, most RNA is non-coding and is largely understudied as structural, functional, and therapeutic characterization remains challenging. Though small molecules are useful tools to probe these properties, RNA is particularly challenging to target with traditional non-covalent ligands due to its dynamic nature. To overcome challenges with RNA dynamics, covalent chemistry can be utilized as RNA nucleotides contain nucleophilic positions that can react with electrophilic warheads, such as the 2’-hydroxyls that react with SHAPE reagents. Reacting RNA nucleotides with electrophiles will allow for a better understanding of reactivity with RNA. However, canonical and commercially available RNA nucleotides (NMPs) do not mimic RNA due to differences in the phosphate charges and the presence of a 3’-hydroxyl group. To address this gap, I designed RNA nucleotide mimetics that model the electronic environment of RNA; they contain ethylated phosphates with a -1 charge on both the 3’- and 5’-positions to mimic the charge state of an oligonucleotide while the ethyl groups mimic the “turn” of an additional nucleotide. Once synthesized, I will react these molecules in vitro with a library of diverse electrophiles and measure covalent bond formation by LC/MS. I will then utilize HPLC to quantify percent covalent bond formation of each reaction and NMR to identify where covalent bond formation occurred. I expect this screen to provide insights into RNA nucleotide reactivity, opening the door to capturing RNA selectively and elucidating the functions of this biological enigma.
Ye Yuan1, Amanda Linskens1, Swathi Yadlapalli1,2
Cellular and Molecular Biology1 and Cell and Developmental Biology2, University of Michigan Medical School, Ann arbor, Michigan, 48109 USA
Abstract:
Introns are traditionally viewed as mainly influencing alternative splicing and protein diversity. However, our study reveals a novel function for a specific intron in timeless mRNA, a Drosophila clock mRNA, that introduces a critical delay in gene expression, extending beyond its conventional roles. Using RNA Fluorescent In Situ Hybridization and RNA-sequencing, we observed that approximately 50% of timeless mRNAs—key components of the Drosophila circadian clock—remain nuclear due to a unique intron retention event. This intron is spliced out post-transcriptionally near the nuclear speckles, introducing a vital 2-hour delay in circadian rhythms. Furthermore, CRISPR-mediated deletion of this intron leads to rapid mRNA accumulation in the cytoplasm, accelerated TIM protein synthesis, and a shortened circadian cycle of ~22 hours. Additionally, this intron, which lacks a traditional branch point, when inserted into reporter minigene transcripts, is sufficient for nuclear retention of any mRNA in both Drosophila neurons and human U2OS cells—a process that is reversible by introducing a lariat branch point. We also demonstrate that the RNA-binding protein Qkr58E-2, homologous to mammalian Sam68, is crucial for activating this splicing; its knockdown results in increased nuclear retention of timeless mRNA, reduced TIM protein levels, and disrupted circadian rhythms. These findings unveil a novel rate-limiting mechanism within circadian clocks, highlighting the significant regulatory role of intron splicing dynamics in gene expression. Our study reveals a critical role for introns in timing gene expression, introducing them as key regulatory elements in circadian rhythms and potentially broader biological processes.
Dana Beseiso1, Kesang Gawa1, Dr. Rachel Niederer1
Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Abstract:
The expression of various messenger RNA (mRNA) isoforms by a singular gene is essential for promoting cellular diversity and adapting to stress. Alternative transcription start site (TSSs) usage results in mRNAs that differ in their 5′-ends and, as a result, their 5′ untranslated regions (5′ UTRs). 5′ UTRs harbor translational control elements that modulate protein output, but it remains poorly understood whether alternative TSS usage is broadly employed as a mechanism to modulate protein abundance, especially throughout disease progression. We hypothesize that widespread changes in TSS usage drive translational reprogramming which promotes the cellular and morphological changes necessary for cancer progression. Using luciferase reporters, we show that annotated 5′ UTR isoforms of the metastasis-associated proteins, NODAL, NANOG, and SNAIL, are differentially translated in human cancer extracts and identify a putative translational control motif. To identify global changes in TSS usage with the potential to alter protein expression in cancer, we utilize a series of breast cancer cell lines representing increasingly aggressive cancer states and perform ReCappable-seq. We anticipate that widespread alternative TSS usage throughout metastatic progression will produce distinct 5′ UTR isoforms that alter translational output via enhancer or repressor motifs. Identifying novel translational control elements in 5′ UTRs will elucidate their role in modulating gene expression and inform novel anticancer therapeutic strategies.
Zhengde Liu1*, Velina Kozareva2*, Sahba Seddighi3*, Sasha Rollinson1*, Yue A. Qi4*, Stanislav Tsitkov2*, Tiffany Huang1*, Michael E. Ward3*, Ernest Fraenkel2*, Sarah Kargbo-Hill1*
Department of Molecular Cellular and Developmental Biology, University of Michigan1, Department of Biological Engineering, MIT2, National Institute of Neurological Disorders and Stroke, NIH3, Center for Alzheimer’s and Related Dementias, NIH4
Abstract:
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two devastating neurodegenerative disorders that remain without a cure. TDP-43, a DNA/RNA-binding protein that forms pathologic aggregates in ALS and FTD pathology, plays a critical role in RNA regulation, encompassing transcription, splicing, RNA transport, and stability. Loss of nuclear TDP-43 is an early pathologic feature of ALS and FTD, proceeding TDP-43 protein aggregation and likely contributing to disease progression. One important function of TDP-43 is splicing repression. Loss of nuclear TDP-43 leads to a deficit in splicing repression and an increase in cryptic splicing, in which an intronic sequence, called a cryptic exon, is retained in the mature spliced RNA. Cryptic splicing often leads to RNA instability and degradation. By depleting TDP-43 in human iPSC-derived neurons (i3Neurons), we observed 100s of cryptic exon inclusions, including a cryptic exon in CELF5. CELF5 is an RNA-binding protein in the CUGBP Elav-like family of RNA-binding proteins. Other family members have been shown to functions in RNA regulation and neurodevelopment, however little is known about the precise roles of CELF5. We observed intriguing parallels between CELF5 and TDP-43, including shared binding motifs and regulatory targets. Further studies CELF5 may reveal mechanisms behind the pathological contribution of nuclear TDP-43 loss in neurodegeneration and provide more insights into potential therapeutic applications.
Ibukunoluwa K. Self1, Cristina H. LabMember1, David C. Mentor1*
Departments of Pharmacology and Biochmistry1, UT Southwestern Medical Center, Dallas, Texas, 75390
Abstract:
RNA interference, or RNAi, is a crucial biological mechanism in gene silencing. Through the loading of microRNAs (miRNAs) into RISC complexes containing the protein, Argonaute 2 (Ago2), the mechanism can cleave or inhibit translation in target RNAs.
Based on the knowledge that RNAi takes place in the nucleus as well as the cytoplasm, we wanted to deduce whether the nuclear RNAi mechanism is specific to the nucleoplasm or if it takes place in the chromatin as well. We hypothesized that RNAi factors and interactions could be found in all fractions of a chromatin fractionation sample of wild-type HCT-116 cells. We did this by utilizing cell culture techniques, as well as Ago2-Chromatin Immunoprecipitation (Ago2-ChIP) protocols, bicinchoninic acid (BCA) assays, and western blotting.
Our experiments found that various RNAi factors, including the Argonaute 2 and TNRC6A proteins, could be found in the cytoplasmic, nucleoplasmic, and chromatin fractions of the wild-type HCT-116 cells. Via Ago2-ChIP, we also found that Ago2 interacts with TNRC6A in chromatin fractions.
The results indicate that the RNAi mechanism takes place in the chromatin as well as the cytoplasm. Furthermore, the varied signals of each factor in the chromatin compared to the cytoplasm could raise discussions for varied mechanism expression in different regions of the cell. The knowledge of the specific locations in which RNAi takes place provides us with more insight into the mechanism, which is crucial to the regulation of gene expression.
Phillip J. McCown, Felix Eichinger, Matthew Manninen, Fadhl Alakwaa, Damian Fermin, Abhijit S. Naik, Sean Eddy, Matthias Kretzler
Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan, 48109, United States.
Introduction
The importance of long non-coding (lnc) RNA involvement in biology is increasingly recognized. By remapping transcriptomic datasets from human kidneys, we can identify lncRNAs involved in disease processes with cell type selectivity.
Methods
We evaluated different lncRNA annotation sources. A modified GeneTransferFile (GTF) was created incorporating the lncRNAKB (version 6) and Ensembl GTFs (GRCh38) into a non-redundant GTF, named lEG (lncRNAKB-Ensembl GTF). Three kidney biopsy datasets, comprising 59 patients, were remapped using lEG, effectively annotating genes and lncRNAs within one pipeline.
Results
Our non-redundant lEG contained 102,420 mRNA and lncRNAs. In kidney biopsy datasets, we mapped >= putative 25,000 lncRNAs in bulk and scRNA-seq profiles. This included previously undetected lncRNAs. In scRNAseq, at least 91 lncRNAs clustered discretely in glomerular, tubular, or immune cells with up to 84.5% specificity.
Conclusion
The lEG allows efficient gene-lncRNA mapping in a single pipeline, enabling rapid quantitation of lncRNA expression alongside gene profiles reducing the need to remap sequencing profiles for different use cases. We demonstrate lncRNAs with selective cell type expression and in disease states in human kidneys. Use of this approach can further our understanding in the etiology of several kidney diseases, while also possibly revealing therapeutic targets or diagnostic markers.
Chathuri Pathirage, Kaley Simcox, Maddy Zamecnik, Kristin Koutmou
Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA
Abstract:
tRNAs are the most modified among all nucleic acid species. While modifications in the tRNA anticodon loop directly contribute to translation-related functions in the ribosome, the functions of tRNA body modifications are less known. One example of such a modification is dihydrouridine (D) – the second most abundant tRNA modification across biology. D is found at multiple positions in D loop that is important for tRNA tertiary structure and has been implicated in maintaining levels of specific tRNAs. Nonetheless, no specific role has been identified for this modification in protein synthesis or cellular homeostasis. Adding to this mystery, dihydrouridine synthases (DUS) enzymes are dispensable for Saccharomyces cerevisiae growth under normal laboratory conditions. We hypothesized that the D on tRNAs has specific translation-related function in cells under unique stress conditions, as has been shown for several other tRNA modifications. To understand the molecular level function of D, a S. cerevisiae growth screen was used to test if the lack of DUS enzymes affects cell survival under stress conditions such as alternative carbon sources, metal ions, ribosome inhibition, oxidative stresses and temperature. While DUS mutants grew like WT cells under most conditions, DUS 1 and 4 mutants displayed severe growth phenotypes in the presence of translation inhibitors, hygromycin and cycloheximide. Preliminary in vitro translation data suggests that tRNAs lacking D, have improved translocation in the presence of hygromycin. Taken together, these results suggest that D modification in tRNA is involved in fine-tuning translation speeds, particularly at the translocation step in protein synthesis.
Emily Slobodenyuk1, Brittany Bowman2, Chase Weidmann2
1. Cellular and Molecular Biology Program, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
2. Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Abstract:
Calmodulin (CaM) is an essential, highly conserved, ubiquitously expressed calcium-binding protein, and interacts with many proteins to regulate a myriad of cellular functions, including the cell cycle, cell motility, and the regulation of ion channels. Due to calmodulin’s importance, mutation in the calmodulin gene or misregulation of the protein contributes to cancer, heart disease, and neurological disorders. Interestingly, in mammals, three CaM genes at three separate autosomal loci express divergent mRNA that each encode an identical calmodulin protein (CALM1, CALM2, CALM3). Expression of CaM varies in different tissues, variants localize in unique patterns, and mutations in each CaM gene yield distinct phenotypes. The idea of unique transcript roles is further supported by evolutionary conservation, as there is a higher degree of conservation of CaM variants between species than between the CaM variants within each species, especially in their 3′UTRs. Therefore, we hypothesize that sequences within the 3′UTRs govern mRNA localization, with local translation of the transcripts determining the subcellular localization of CaM protein, and thus, unique signaling responses. We will determine the contribution of each transcript to the total protein and determine if there are transcript-specific protein compartments using RNA FISH and immunofluorescent tagging of each protein. We will determine the cis-regulatory elements necessary for the localization of the transcripts by chemical probing and genetic screening/ We hope to better understand the transcript-level regulation of CaM genes, with the resulting knowledge being broadly applicable to other RNAs.
Leidy Vanegas-Cano1 and Rachel O. Niederer1
Department of Biological Chemistry1, University of Michigan, Ann Arbor, Michigan 48109, USA
Abstract:
Pseudouridine (Ψ) is the most ubiquitous modification across eukaryotic ribosomes. Dyskerin (DKC1), the primary pseudouridine synthase responsible for rRNA pseudouridylation, utilizes small nucleolar RNA (snoRNA) as a guide to direct the specific positioning of uridine at its active site, where the enzyme subsequently modifies the rRNA. In mammalian cells, DKC1 deficiency also shows compromised translation initiation and fidelity. Despite evidence linking rRNA pseudouridylation to ribosome function, how these modifications are regulated and their role in selective mRNA translation remain unclear. To investigate this, we examined whether DKC1 expression levels influence ribosome pseudouridylation and mRNA translation. Using the Genotype-Tissue Expression (GTEx) Portal, we selected three cell lines with varying DKC1 expression, ranging from low to high abundance: SKOV3 (Ovarian adenocarcinoma), 549 (lung adenocarcinoma), and Hep G2 (hepatocellular carcinoma). Western blot analysis showed lower DKC1 expression in SKOV3 compared to A549 and Hep G2, which disagrees with the expression data from the GTEx Portal. In vitro translation assays revealed significantly higher translation activity in SKOV3 extracts than in A549 and Hep G2, suggesting that intrinsic factors in SKOV3 cells may enhance translation efficiency, possibly through ribosome modifications or associated protein interactions. Future Nanopore RNA sequencing experiments will measure rRNA pseudouridylation levels and identify cell-specific Ψ sites in these lines. This study establishes a foundation for exploring how natural variation in DKC1 expression influences rRNA pseudouridylation and its impact on mRNA recruitment by ribosomes.
Abigail Kelly, Kipchumba Kaitany, Alex Bzdula, Markos Koutmos
Department of Chemistry
Abstract:
Ribonuclease Proteins (RNase Ps) are a class of enzymes responsible for cleaving the 5′ leader sequence of premature tRNAs (pre-tRNA). In 1998, a subclass of RNase P was discovered in the human mitochondria, termed protein-only RNase Ps (PRORPs), which were not catalytically driven by RNA. The complex consisted of PRORP, the catalytic center, and two accessory proteins required for efficient cleavage- TRMT10C, a methyltransferase, and SDR5C1, a dehydrogenase. Later, single subunit PRORPs were discovered in non-metazoan eukaryotes. Much of what we know about these enzymes comes from studies in plants such as Arabidopsis thaliana (At). While these single subunit PRORPs do not contain accessory proteins like Metazoan mitochondrial (mt)-RNase Ps, it was recently discovered that At-PRORP2, a nuclear enzyme, interacts with methyltransferases At-TRM1A and At-TRM1B. Knockout of both methyltransferases are lethal to plant growth and pre-tRNA processing. I am conducting assays to determine 5′ cleavage rates for different At-tRNAs via gel-based assays, as well as fluorescent polarization, to discover if the enzyme has a sequence or structural preference for cleavage. Additionally, I am working to purify At-TRM1A and At-TRM1B to see what effect they have on cleavage rates and binding affinities. It has been shown that miscleavage occurs in vitro for specific At-tRNAs. I am investigating which At-tRNAs are prone to miscleavage and if TRM1A and TRM1B can rescue these miscleavage events. My project aims to better elucidate the PRORP interactome and serves as a model for understanding human mt-RNase P, which is more complex and has biological disease relevance.
Amelia Cochran, Jacqueline Anthenien, Kristin Koutmou, Markos Koutmos
Department of Chemistry, University of Michigan, Ann Arbor, Michigan, 48109
Abstract:
Pseudouridine synthase (Pus) enzymes catalyze the isomerization of uridine (U) to pseudouridine (Ψ), a common RNA modification known to impact stability and structure. Originally characterized as modifiers of non-coding RNAs, some Pus enzymes are now also known to target mRNA. Because Ψ can impact various parts of the mRNA life cycle, these mRNA-modifying Pus enzymes may regulate gene expression. But how these mRNA targets are selected is not yet fully understood. Pus4, which modifies U55 in the T-loop of tRNAs, is one of the major mRNA-modifying Pus enzymes. Though it has been proposed that Pus4 modifies mRNA targets that mimic its tRNA target in sequence and secondary structure, recent studies show that some mRNAs without these properties can also be modified. This suggests that there is more to learn about what defines Pus4’s mRNA substrate scope. To better understand how RNA features impact Pus4 substrate selection, we are characterizing Pus4’s ability to bind and modify RNAs of different sequences and structures in vitro. Additionally, we aim to understand how Pus4’s structural features contribute to its substrate selection, and how differences between prokaryotic and eukaryotic homologs influence apparent differences in specificity. We have observed a lack of selectivity in RNA binding that is unique to eukaryotic Pus4, and preliminary data suggests Pus4 can modify substrates in vitro that differ from its native target. This points to the potential for a broad substrate scope governed by factors outside of protein-RNA recognition.
Ri Tang 1,2#, Xiubin Liang 3#, You Xu 1, Yang Liu 3,4,Shimiao Liao 1, Qiyan Wang 1, Zitong Wang 1, Xiang Liu 1, Jie Xu 3, Guizhi Zhu 1,4,5 *
1 Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA
2 Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 Shanghai, China
3 Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
4 Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
5 Bioinnovations in Brain Cancer, Biointerfaces Institute; Center for RNA Biomedicine. University of Michigan, Ann Arbor, MI 48109, USA
Abstract:
The development of gene therapies for cystic fibrosis (CF) is hampered by the limitations of current cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, which fail to benefit approximately 30% of CF patients due to specific genetic mutations. Here, we disclose pulmonary delivery of circular RNA (circRNA) encoding wildtype functional CFTR protein (circRNA-CFTR), for the CFTR-mutant-agnostic treatment of CF patients. circRNA-CFTR is featured with high biostability, long-lasting expression of CFTR protein in lung epithelial cells. For the pulmonary delivery of circRNA-CFTR, we used an Design of Experiment (DOE) approach and identified lead lipid nanoparticles (LNPs) that enabled efficient protein expression in mouse lung, upon intratracheal administration of circRNA-loaded LNPs. Further, upon intratrachal administration in mice, these LNPs enabled circRNA delivery to mouse upper tracheal epithelial subtypes, such as ciliated cells and ionocytes, of which the normalization of CFTR physiological function is pivotal for CF-associated lung diseases. The resulting circRNA-CFTR-loaded LNPs showed efficient CFTR protein production in CF patient-derived bronchial epithelial cells without invoking strong immune responses, resulting in the restoration of the physiological function of CFTR to pump Cl- across the cell membrane in these cells. Furthermore, in a genetically engineered CF mouse model with CFTR loss-of-function mutation, circRNA-CFTR-loaded LNPs resulted in efficient CFTR expression in mouse tracheal epithelia , as shown by ex vivo tissue immunofluorescence imaging, and hence restored the CFTR function of a chloride channel, as shown by a Ussing chamber experiment in tracheal epithelia.
Anbarasu Kumaraswamy1,2, Rahul Mannan3,4, Olivia A. Swaim1,2, Eva Rodansky1,2, Xiao-Ming Wang3,4, Aaron Udager3,4, Rohit Mehra3,4, Hui Li5, Colm Morrissey6, Eva Corey6, Michael C. Haffner7,8,9, Peter S. Nelson7,8,9, Arul M. Chinnaiyan2,3,4,10,11, Joel A. Yates1,2, Joshi J. Alumkal1,2,4.
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA1
Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA2
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA3
Michigan Center for Translational Pathology, Ann Arbor, MI, USA4
RevMAb Biosciences, Burlingame, CA, USA5
Department of Urology, University of Washington, Seattle, WA, USA6
Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, USA7
Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA8
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA9
Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA10
Howard Hughes Medical Institute, Ann Arbor, MI, USA11
Abstract:
Lysine-specific demethylase 1 (LSD1) is a histone demethylase and regulator of differentiation, including in cancer. A neuronal-specific isoform of LSD1—LSD1+8a—has been shown to play a key role in promoting neuronal differentiation in the developing brain. We previously determined that LSD1+8a transcripts were specifically detected in an aggressive subtype of prostate cancer harboring a neuronal program—neuroendocrine prostate cancer (NEPC)—but not in prostate adenocarcinomas harboring a glandular program. However, the number of samples examined were limited. Herein, using a large collection of prostate cancer patient tumor models and tissue samples, we determined that LSD1+8a mRNA expression was detected in every NEPC tumor examined by quantitative polymerase chain reaction (qPCR) and RNA in situ hybridization (RNA-ISH), while we failed to detect LSD1+8a in any prostate adenocarcinoma tumor. Finally, we also generated a rabbit monoclonal antibody specific to LSD1+8a protein and confirmed its specificity using normal neuronal tissue samples. However, LSD1+8a protein was not detectable in NEPC tumors—likely due to the substantially lower levels of LSD1+8a mRNA in NEPC tumors vs. normal neuronal tissues. In summary, our data suggest that LSD1+8a mRNA measurement is a sensitive and specific method to diagnose NEPC, which is often challenging.
Hideyuki Komori1*, Aifu Li2, Kin Fai Au2, Cheng-Yu Lee1
Life Sciences Institute1 and Department of Comutational Medicine and Bioinformatis2, University of Mihigan, Ann Arbor, Mihigan 48109, USA
Abstract:
Pediatric brain tumors arise from progenies of neural stem cell (NSC)s in developing brain and malignant brain tumor cells show NSC-like properties. Mechanisms how tumor cells acquire NSC-like properties have not fully understood yet. To investigate the mechanisms, we have employed Drosophila larval brain tumor as a model system. In the fly larval brain, RNA-binding protein, Brat timely binds to 3’UTR of target transcripts and robustly induces decay of selected NSC gene transcripts in NSC progenies that initiate differentiation. However, it has been unclear how Brat promotes robust decay of selected NSC gene transcripts have not been unclear. We raised hypothesis that N6-methyladenosine (m6A) modification may facilitate decay of specific Brat target transcripts. To test this hypothesis, we initially investigated correlation of m6A and Brat-mediated mRNA decay by performing direct mRNA sequencing to profile m6A and short-read mRNA sequencing to identify genes downregulated by Brat. We found that mRNAs possessing m6A in 5’UTR and Brat-binding sequences in 3’UTR are sensitive to Brat compared to mRNAs possessing only Brat-binding sequences, suggesting that m6A in 5’UTR may promote Brat-mediated mRNA decay. Consistently, mettl3 and ythDF are required for Brat-mediated mRNA decay to suppression of tumor formation in the larval brain. Our results suggest a possibility that YTHDF bound to m6A on 5’UTR connects with Brat on 3’UTR, facilitating decay of specific NSC gene transcripts in NSC progenies. Our data provide a new model to explain how m6A modification links to RNA-binding protein-mediated mRNA decay to suppress tumorigenesis during normal brain development.
Hemant N. Goswami 1 , Fozieh Ahmadizadeh 1 , Bing Wang 1 , Doreen Addo-Yobo 2 , Yu Zhao 1 , A. Carl Whittington 3 , Huan He 1 , Michael P. Terns 4 and Hong Li 1 , 2
1 Institute of Molecular Biophysics, Florida State University, Tallahassee, FL 32306, USA 2 Department of Chemistry and Biochemistry, Florida State University, Tallahassee, FL 32306, USA 3 Department of Biological Sciences, Florida State University, Tallahassee, FL 32306, USA 4 Biochemistry and Molecular Biology, Genetics and Microbiology, University of Georgia, Athens, GA 30602, USA
Abstract:
The type III-A CRISPR–Cas systems (Csm) are sophisticated defense mechanisms used by bacteria to protect against viruses. These systems are activated by RNA molecules derived from invading viruses and perform multiple functions: degrading single-stranded RNA and synthesizing small signaling molecules called cyclic oligoadenylates (cOAs). These cOAs, produced by the Cas10 subunit, act as molecular messengers to trigger additional antiviral responses. Interestingly, different forms of cOAs—cA3, cA4, and cA6—can be produced, each with the potential to activate distinct pathways. However, the process by which Cas10 generates specific cOA isoforms and controls their lengths remains poorly understood.
In this study, we investigate how the Csm complex synthesizes cA6, one of the longer cOA molecules. Using structural and biochemical analyses, we reveal that Cas10 adds adenine units sequentially in a 3′-to-5′ manner during cA6 synthesis, unlike conventional RNA polymerases. We identified three key sites along the elongation path where adenine binds, including a unique tyrosine–threonine dyad that is specific to cA6-producing enzymes. Mutating this dyad disrupts cA6 synthesis, shifting production to shorter cA4 molecules, thereby highlighting its critical role in determining cOA chain length.
Our findings shed light on how bacteria use Cas10 to regulate signaling molecule synthesis with remarkable precision. This work provides a deeper understanding of RNA-triggered molecular signaling pathways and co-evolution of CRISPR enzymes with the downstream cOA sensors.
Shubham Choudhury1, Nisha Bajiya1, Sumeet Patiyal1 and Gajendra P. S. Raghava1*
Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, 110020, India
Abstract:
In the past, several methods have been developed for predicting the single-label subcellular localization of messenger RNA (mRNA). However, only limited methods are designed to predict the multi-label subcellular localization of mRNA. Furthermore, the existing methods are slow and cannot be implemented at a transcriptome scale. In this study, a fast and reliable method has been developed for predicting the multi-label subcellular localization of mRNA that can be implemented at a genome scale. Machine learning-based methods have been developed using mRNA sequence composition, where the XGBoost-based classifier achieved an average area under the receiver operator characteristic (AUROC) of 0.709 (0.668–0.732). In addition to alignment-free methods, we developed alignment-based methods using motif search techniques. Finally, a hybrid technique that combines the XGBoost model and the motif-based approach has been developed, achieving an average AUROC of 0.742 (0.708–0.816). Our method—MRSLpred—outperforms the existing state-of-the-art classifier in terms of performance and computation efficiency. A publicly accessible webserver and a standalone tool have been developed to facilitate researchers (webserver: https://webs.iiitd.edu.in/raghava/mrslpred/).
Visweswaran Ravikumar1,2, Ryan Rebernick2,3, Anbarasu Kumaraswamy1,4, Eva Rodansky1,4, Joel Yates1,4, Aaron Udager2,4, Arul Chinnaiyan1,3,5,6, Marcin Ceislik2,4,5, Arvind Rao1,2,7,8, Joshi J. Alumkal1,4
1Rogel Cancer Center, 2Department of Computational Medicine and Bioinformatics, 3Department of Pathology, 4Department of Internal Medicine, 5Michigan Center for Translational Pathology, 6Department of Urology, 7Department of Biostatistics, 8Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
Abstract:
Prostate adenocarcinomas are the most common form of the disease. Targeting the nuclear hormone receptor, the androgen receptor (AR), is the principal treatment strategy. However, resistance is common. Lineage plasticity (LP)—change in differentiation state—is increasingly recognized as one mechanism of resistance to AR-targeting therapies. LP is a continuum, but neuroendocrine prostate cancer (NEPC) is the most lethal example in which tumors lose AR expression and undergo neuroendocrine differentiation. Despite the increasing incidence of NEPC due to more widespread use of new and potent AR inhibitors, mechanisms by which NEPC emerges after therapy have not been well-studied due to the paucity of matched patient tumors. To address this deficit, we performed multi-omic bulk and spatial profiling of matched biopsies from seven patients with prostate adenocarcinoma tumors that underwent LP to NEPC after treatment.
Analysis of bulk profiling for genomic alterations and gene expression revealed specific expression programs and mutations enriched in baseline tumors that eventually underwent NEPC LP. Importantly, we identified two distinct NEPC programs at progression associated with status of the RB1 tumor suppressor gene. To further clarify tumor heterogeneity, we performed spatial transcriptomic profiling. We identified significant inter- and intra-patient heterogeneity, with tumor cells in distinct states driven by the AR, specific neuronal factors, or hybrid states expressing both AR and neuronal programs. Copy number inference identified multiclonality within many tumor lesions possibly driving tumor heterogeneity. This demonstrates the need to target multiple tumor clones to control NEPC more effectively.
Niloofar Khairkhah*1, Riley Bigger*1,2, Rhea Sridhara1, Hernando Lopez-Bertoni 3, Stefanie Galban*1,4,5
1 Department of Radiology and Surgery, The University of Michigan Medical School, Ann Arbor, MI 48109, United States
2 Department of Biological Chemistry, The University of Michigan Medical School, Ann Arbor, MI 48109, United States
3 Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, United States
4 Center for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, MI 48109, United States
5 Rogel Cancer Center, The University of Michigan Medical School, Ann Arbor, MI 48109, United States
Corresponding author at: Center for Molecular Imaging, Department of Radiology, The University of Michigan, BSRB A502, Ann Arbor, MI 48109, United States
Abstract:
Diffuse Midline Gliomas (DMGs) are highly aggressive gliomas that account for ~20% of pediatric central nervous system tumors. The H3K27M-altered subset is particularly lethal, with 100% tumor recurrence and no effective long-term treatments. Thus, a desperate need to develop new therapeutic avenues remains. RNA therapies, a new class of therapeutics that include microRNA (miRNA) therapies, utilize RNA mimetics to target and treat cancer and other diseases. Compared to single-target small molecule inhibitors, miRNAs represent potent future tools capable of simultaneously targeting multiple aberrant signaling pathways in DMG to increase therapeutic efficacy and prevent tumor resistance and recurrence.
To identify targetable, aberrant gene expression in H3K27M-mutated DMG, we performed RNA sequencing of nascent, newly synthesized RNA in the human DMG cell line SU-DIPG-XIII and its isogenic pair SU-DIPG-XIII-H3K27M-KO, where oncohistone expression is prevented by CRISPR gene editing. We compared transcriptional profiles in isogenic cells to render a list of potential disease/tumor-driving genes, expressed solely in H3K27M DMGs, that can be targeted. Computational analysis using miRNet identified miRNAs hsa-miR-124-3p, hsa-miR-27a-3p, and hsa-miR-146a-5p as promising candidate RNA mimetics to develop as new therapeutic options for DMG H3K27M-altered. These miRNAs are predicted to each target 300-400 genes upregulated specifically in H3K27M DMGs, highlighting the powerful capability of this new class of RNA therapeutics. Notably, preliminary proliferation assays in SU-DIPG-XIII cells showed that DMG-specific miRNAs significantly reduced tumor cell growth, highlighting their therapeutic potential.
To evaluate efficacy and cellular consequences of identified miRNAs in a panel of human and murine DMG H3K27M-altered cells, we have employed an inducible lentiviral system that allows for precise on/off gene regulation with miRNA mimetics. This system enables controlled manipulation of gene expression, providing a powerful tool to study the functional consequences of miRNAs in various cellular contexts. Furthermore, the panel of DMGs with inducible miRNA will be utilized for in vivo testing in relevant orthotopic models and adapted to the PiggyBac intrauterine electroporation DMG model. Our research will pioneer the use of microRNA mimetics as the first proof-of-concept study of using DMG-specific miRNAs to control aberrant gene expression. While this strategy demonstrates significant promise, we acknowledge that advancements in RNA delivery methods will be essential for translating this approach into a clinical reality in the future.
In summary, our findings will provide proof-of-concept for use of a new class of RNA therapeutics for the development of innovative future therapies for DMG
Max Baymiller1, Stephanie L. Moon1,2
1. Department of Human Genetics, University of Michigan; 2. Center for RNA Biomedicine
Abstract:
During the cellular response to stress, translation initiation is suppressed via phosphorylation of eIF2α and non-translating mRNAs condense into RNP granules including stress granules and P-bodies. The stress response is active in many diseases including neuropathies caused by mutations in tRNA synthetases, where preventing the stress response is therapeutic. We hypothesized that tRNA synthetase activity is required for stress-induced RNP granule formation by facilitating ribosome runoff. We found that despite P-eIF2α induction by tRNA synthetase inhibitors, stress granule and P-body formation was inhibited. Formation of these RNP granules was rescued upon mRNA release from ribosomes by puromycin. tRNA synthetase activity was also required for arsenite-induced stress granules, further indicating loss of tRNA charging traps mRNAs within polysomes during stress. We observed ribosome-associated quality control factor ZNF598 was activated upon tRNA synthetase inhibition, an indication of ribosome collisions. Yet, ZNF598 depletion did not increase P-eIF2α levels or further decrease stress granules, suggesting ribosome collisions are a minor contributor to tRNA charging stress. Together, these results show that tRNA synthetases are critical for mRNA to cycle from the translating pool into stress-induced RNP granules. Defects in translation elongation that occur in other stresses such as UV and amino acid starvation may also impair RNP granule assembly in this manner. Identifying molecular mechanisms of ribosome rescue that enable RNP granule formation could inform therapeutics for diseases associated with tRNA synthetases or tRNA metabolism.
Gregory Bick1,2, Yijuan Zhang1, Bin Ouyang1, Arame Diouf 2, Mahendra Jadhao1, Xiaoting Zhang1,2,3
1. Department of Cancer Biology, University of Cincinnati, Cincinnati, OH. 2. RNA Nanotherapeutics, Mason, OH. 3. Breast Cancer Research Program, University of Cincinnati, Cincinnati, OH.
Abstract:
Despite decades of research breast cancer remains a leading cause of cancer-related deaths among women. Estrogen receptor-positive (ER+) breast cancers account for about 75% of all breast cancer cases and anti-estrogen therapies are widely used in treatments. Unfortunately, approximately 50% of these tumors become resistant and metastasize to vital organs. Recent work has established MED1 as a key tissue-specific ER coactivator in mediating tumor growth, metastasis, and resistance to anti-estrogen therapies. We have developed a pRNA-HER2apt-siMED1 nanoparticle harboring two MED1 siRNAs and a HER2 aptamer for tumor targeting using a 3-WJ phi29 packaging RNA backbone. Here, we demonstrate scale-up manufacturing and the homogeneous formation of RNA nanoparticles even in conditions more extreme than physiological. These nanoparticles specifically target breast cancer cells to block production of MED1 proteins in vitro and in vivo in preclinical breast cancer models. Biodistribution studies showed that these nanoparticles primarily accumulated in the tumor with only residual signals observed in the liver and kidney. Significantly, once-per-week intravenous injection of the pRNA-HER2apt-siMED1 nanoparticles achieved greater tumor growth inhibition than 5 times weekly tamoxifen treatment in vivo in breast cancer orthotopic xenograft models and could greatly inhibit tumor growth over 90% in 2 patient-derived-xenografts. Importantly, we observed no significant changes in body weight, behavior, hematology, liver, kidney, heart health, and immunogenicity in wild-type mice even at 10X-over the therapeutic dose in both short-term dose-escalation and long-term repeated treatment studies. Together, these data support the safety and efficacy of pRNA-HER2apt-siMED1 nanoparticles and their potential use in breast cancer patients.
Phillip J. McCown1*, Edgar A. Otto1, Damian Fermin1, John R. Hartman1, Mathew O. Alaba1, Maria Larkina1, Michael Arbit1, Margaret Helmuth1, Brad A. Godfrey1, Sean Eddy1, Laura H. Mariani1, Abhijit S. Naik1, Maarten Hoek2, Terry Satterfield2, Matthias Kretzler1
University of Michigan, Michigan Medicine, Ann Arbor, MI, United States1; Maze Therapeutics Inc, South San Francisco, CA, United States 2
Background:
Single nuclear RNA sequencing (snRNAseq) of biopsies affords insight to molecular and cellular pathways in kidneys. In the NEPTUNE consortium, biopsy samples of participants with nephrotic syndrome(NS) have been curated for snRNAseq. While small studies have provided insights using subsets of samples, an omnibus of transcriptional data from numerous samples may aid further discovery and research.
Methods:
snRNAseq (n=11) and single cell RNA sequencing (n=47) from kidney biopsies from healthy living donors and transplant recipients in the Michigan HKTTA study were integrated with snRNAseq of 120 biopsies from patients with FSGS, MCD, IgAN, and other kidney diseases enrolled in the NEPTUNE Consortium to identify clusters of cells. Whole genome sequencing data from blood samples of 90 NEPTUNE participants were used to assess APOL1 genotype.
Results:
Nuclei and cells (n=1,047,781) resolved into 28 clusters of kidney resident and non-resident celltypes, including a novel cluster of transitioning parietal epithelial cells. APOL1 risk alleles were present in 90participants. Among kidney cell types, we observed the strongest correlation between APOL1 mRNA levels and JAK-STAT activity in podocytes in participants with FSGS with at least one copy of the G1 APOL1 risk allele.
Conclusion:
This Omnibus of CElls And Nuclei (OCEAN) from NEPTUNE participants with NS and IgAN is a large set of molecular and clinical data that allows unique analyses that can provide novel insights into mechanisms of kidney diseases.
Fatemeh Fattahi1, Laura Vallance1, Julia Holden1, Kareem Hussein1, Brandon Tepper1, Joshua Meier1, Steven Huang, Ulus Atasoy1,3
1- Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI
2- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, University of Michigan Medical School, Ann Arbor, MI
3- Division of Allergy-Immunology, Ann Arbor VA Health System, Ann Arbor, MI
Abstract:
Allergic asthma remains challenging to manage despite advancements in biologic therapies targeting cytokines such as IL-4 and IL-13. Current treatments fail to address underlying disease drivers, necessitating innovative approaches targeting upstream regulatory mechanisms. While transcriptional regulation has been extensively studied, posttranscriptional gene regulation by RNA-binding proteins (RBPs) remains underexplored. The RBP HuR (Elavl1) stabilizes mRNAs encoding Gata3, a master regulator of Th2 differentiation, and Th2 cytokines. Our prior studies demonstrated HuR’s essential role in CD4+ Th2 differentiation by stabilizing Gata3 and Th2 cytokines mRNAs, with conditional HuR ablation in CD4+ T cells abolishing allergen-driven airway inflammation.
In this study, we evaluated KH-3, a selective small-molecule of HuR inhibitor, in a house dust mite (HDM)-induced allergic airway inflammation model. Mice were sensitized intraperitoneally (i.p.) with HDM and rechallenged intratracheally over 2 weeks. KH-3 was then administered i.p. every other day for 2 weeks, resulting in significantly reduced airway inflammation compared to HDM-treated controls. Histological analysis (H&E staining) revealed diminished inflammatory cell infiltration in lung tissue, while bronchoalveolar lavage fluid (BALF) analysis showed reduced eosinophils and Th2 cytokines (IL-4, IL-5, IL-13). qPCR revealed decreased Gata3 and Th2 cytokines mRNA expression, and flow cytometry confirmed reduced Gata3 expression in lung CD4+ T cells.
By targeting HuR, KH-3 offers a novel, promising molecular approach for treating Th2-mediated airway inflammation in allergic asthma. In future studies, we will validate KH-3’s efficacy using CD4+ T cells from asthmatic human lungs in a humanized mouse model of allergic asthma, paving the way for clinical trials using KH-3.
Y. Yuan1, A. Linskens1, R. De Gouvea2, H. Liu2, Y. Xiao2, C. Hsieh1, S. Barmada1, S. Yadlapalli1,2
Cellular and Molecular Biology Training Program1 and Department of Cell and Developmental Biology2, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Abstract:
Circadian clocks are cell-autonomous timekeepers that regulate ~24-hour rhythms in gene expression. While basic mechanisms of circadian transcription-translation feedback are well-understood, spatiotemporal dynamics of clock transcripts and their processing remains unexplored.
Here, we demonstrate that a specific intron (P) of timeless (tim), a Drosophila clock gene, is post-transcriptionally spliced at nuclear speckles, which serves as a novel rate-limiting mechanism in circadian clocks by introducing a delay between transcription of tim mRNA and accumulation of its translatable form in the cytoplasm. Upon transcription, tim mRNAs localize to nuclear speckles, where ‘P’ intron is spliced before nuclear export. Removing this intron causes cytoplasmic accumulation of tim mRNAs, faster accumulation of TIM protein and shortening of the clock to ~22 hours. Inclusion of this ‘P’ intron into reporter minigene transcripts is sufficient for their nuclear localization in both Drosophila neurons and human U2OS cells, and, notably, addition of a 6-bp canonical branchpoint sequence to the intron changes its splicing from post-transcriptional to co-transcriptional. Knockdown of spliceosomal factors, including Prp3 and Prp19, specifically impairs post-transcriptional splicing of the ‘P’ intron, resulting in elevated nuclear retention of tim mRNAs, decreased TIM protein abundance, and disrupted clock. Finally, we found that post-transcriptional splicing at nuclear speckles is a conserved mechanism in other transcripts, including an ALS risk factor unc-13.
Together, our results reveal that post-transcriptional splicing of the timeless ‘P’ intron at nuclear speckles is a rate-limiting step in circadian clocks. Moreover, spatiotemporal dynamics of intron splicing may play underappreciated roles in gene regulation at large.
Yangbo Xiao1, Ye Yuan1, Rafael De Gouvea1, Dunham Clark1, Swathi Yadlapalli1
Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Abstract:
Circadian clocks are cell-autonomous timekeepers that orchestrate 24-hour oscillations in gene expression via conserved transcription-translation feedback loops. While core components of the clock feedback are well-studied, there has been little effort on unbiased, systematic identification of other clock regulators.
We employed BioID-based spatio-temporal proximity labeling to find proteins proximal to Period, a core clock repressor, within clock neurons of Drosophila melanogaster. Surprisingly, out of ~300 high-confidence hits, processing-body (p-body) genes, including pacman (pcm) and maternal expression at 31B (me31b), show significant ontology enrichment. Moreover, fluorescence microscopy shows p-body condensates associate with Period protein and transcripts during late activation phase of the circadian cycle. Disrupting p-body leads to unchanged average level of Period mRNA, constitutive accumulation of Period protein, and repressed transcription of Period gene, showing p-body represses translation of Period transcripts and mediates their degradation. Notably, inclusion of 3’ untranslated region of Period into reporter transcripts is sufficient for their recruitment to p-body condensates and reduced transcript and protein levels.
To summarize, our results demonstrated the dual role of p-body in Period mRNA turnover via interaction with 3’UTR. Furthermore, our study unveiled a new post-transcriptional regulation mechanism of circadian clock involving p-body.
Dhruv Khokhani1,2*, Zhi Duan1,2, Anbarasu Kumaraswamy1,2, Mingchen Shi3, Chao Zhang1,2, Diana Flores1,2, Eva Rodansky1,2, Ya-Mei Hu4, Zheng Xia4, Karan Bedi2, Joel Yates1,2, Michael Haffner5, Yuzhuo Wang3, Joshi Alumkal1,2
Department of Internal Medicine1 and Rogel Cancer Center2, University of Michigan, Ann Arbor, Michigan, 48109, USA
Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada3
Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, 97210, USA4
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109 USA5
Abstract:
Lineage plasticity (LP)—most commonly exemplified by loss of androgen receptor (AR) signaling and switch from a luminal to an alternate differentiation program—is now recognized as a critical determinant of lethality and resistance to AR pathway inhibitors in prostate cancer. Lineage plasticity is a continuum, ranging from AR activity-low tumors to AR-null tumors that do not express a neuroendocrine program (double-negative prostate cancer [DNPC]), and AR-null neuroendocrine (NEPC) tumors. The clarification of factors that are upregulated early in LP is essential to identify tumors that are undergoing or at risk of lineage plasticity.
Our previous study revealed that the transcription factor PROX1 was the most significantly upregulated gene in matched biopsies that underwent LP to DNPC after AR inhibitor treatment. Further analysis of metastatic AR inhibitor-resistant prostate cancer patient tumors, patient-derived xenografts, and cell models determined that PROX1 is upregulated early in the LP continuum in AR activity-low tumors and progressively increases in DNPC and NEPC tumors. Examination of bulk RNA-seq data from patient samples showed a strong inverse correlation between AR and PROX1 expression. Furthermore, analysis of scRNA-seq data from patient samples demonstrated PROX1 was highly expressed in progenitor-like DNPC and NEPC cell populations. Importantly, we determined that DNA methylation regulates PROX1 expression. Finally, we demonstrated PROX1’s functional importance—its suppression in DNPC and NEPC reduces cell survival and impacts apoptosis and differentiation. In summary, our results suggest that PROX1 is a target of interest strongly linked to LP that may promote survival of lethal, AR-independent prostate tumors.
Rachel Giles, Tyler Smith, and Kristin Koutmou
Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA
Abstract:
Cells chemically modify all three major classes of biomolecules (DNA, RNA and protein) to control their structure, function and stability. In RNAs, nucleoside modifications are incorporated either enzymatically or as the result of RNA damage. Regardless of how they are added, the insertion of chemical modifications into mRNA coding sequences can influence translation elongation and termination. Here we investigate the consequences of recently discovered guanosine mRNA modifications, N1-methyl guanosine (m1G) and N2-methyl guanosine (m2G), and a well-established adenosine mRNA modification, inosine (I), on protein synthesis. Non naturally occurring purine modifications, 2,6 – diaminopurine (DAP) and 2-aminopurine (2AP), were also examined. All of these modifications alter the hydrogen bonding potential between codon and anticodon nucleotides as well potential stereochemical interactions between codons and their cognate amino-acyl tRNAs. We find that inclusion of modifications around varied positions of the guanosine base in mRNA codons (GUG, CGU, UGA and UAG) impact translation elongation and termination in a fully reconstituted E. coli translation system. Our findings indicate that these modifications alter the rates of translation elongation and termination in a context dependent manner, with modifications in the first and second positions of the codon slowing elongation the most. These data support the growing body of evidence indicating that mRNA modifications can alter protein production by the ribosome.
Minli Ruan1, Sean M. Engels2, Matthew R. Burroughs2, Dylan Bloch3, Oleksandra Fanari3, Stuart Akeson3, Daniel E. Eyler4, Xiaoyan Li4, Chase A. Weidmann1, Sara Rouhanifard3, Miten Jain3, Lydia M. Contreras2, Kristin S. Koutmou1,4*
1University of Michigan, Department of Biological Chemistry, Ann Arbor, MI 48109
2University of Texas, McKetta Department of Chemical Engineering, Austin, TX 78712
3Northeastern University, Department of Bioengineering, Boston, MA 02120
4University of Michigan, Department of Chemistry, Ann Arbor, MI 48109
Abstract:
RNA. Since its discovery in mRNAs a decade ago, it has been widely speculated that might govern additional post-transcriptional regulation of gene expression. Here, we demonstrate that one of the principal enzymes responsible for adding to mRNAs, pseudouridine synthase 7 (PUS7), accumulates in the cytoplasm under a variety of stress conditions in Saccharomyces cerevisiae and BEAS-2B human epithelial lung cells. The localization of PUS7 to the cytoplasm promotes -incorporation into hundreds of different mRNA sequences and increases cellular fitness under ROS and divalent metal ion stress. Consistent with this result, ~31% of the mRNAs modified when PUS7 is cytoplasmically localized encode proteins present in divalent metal metabolism and ROS stress pathways. Many newly identified -sites lie within portions of the mRNA important for post-transcriptional control—coding regions and 3’ UTRs. Quantitative proteomics reveal that shifts in the cellular post-transcriptional modification landscape upon PUS7 relocalization reshapes the proteome. A significant portion (19%) of proteins exhibiting significant changes in levels in response to PUS7 relocalization bind metal and/or are involved in metal transport. Our data suggest a mechanism whereby stressors localize PUS7 in the cytoplasm to enable the direct modification and regulation of stress response mRNAs, thereby protecting cells from further stress-induced damage.

Madison Turley*, Basma Klump*, Gloria Perez, Chase Weidmann#, Jens Schmidt#
Biomedical Engineering, Michigan State University, East Lansing MI; Department of Obstetrics and Gynecology, Michigan State University, East Lansing MI; Department of Biological Chemistry, University of Michigan, Ann Arbor MI
Abstract:
Telomere shortening is an issue that results from loss of end replication of chromosomes during mitosis. Stem and cancer cells express a ribonucleoprotein called telomerase to combat telomere shortening. Human telomerase consists of telomerase RNA (TR), telomerase reverse transcriptase (TERT), a protein of interest TCAB1, and the H/ACA complex (dyskerin, NHP2, NOP10, and GAR1). The complete assembly and biogenesis of telomerase is still unknown. A technique to analyze bound proteins to RNA is needed to investigate this. Since its development, high-throughput RNA sequencing has preceded various other mutational profiling and sequencing techniques for RNA. One issue with these techniques is that the reverse transcriptase is terminated at regions with bound protein, making the sequencing unable to provide data on RNA-protein assembly. Dr. Chase Weidemann developed a ribonucleoprotein mutational profiling (RNP-MaP) approach that allowed more insight into the assembly of TR and its associated proteins. Our findings provided information on RNA-protein interactions, showing that H2A-H2B and dyskerin binding is independent of the presence of TCAB1. However, TERT typically needs TCAB1 to be bound before it can bind to TR. These findings allowed us to make conclusions about the assembly of telomerase with respect to TR.
Noah Helton1, Ben Dodd1, Stephanie Moon1
Department of Human Genetics1, University of Michigan Medical School, Ann Arbor, Michigan
Abstract:
The integrated stress response (ISR) is critical for resilience to cellular stress and dysregulation is observed in numerous diseases. During the ISR, translation is suppressed and translationally-repressed mRNAs condense into stress granules (SGs). Simultaneously, stress-induced gene mRNAs (e.g. ATF4, GADD34) are selectively translated via upstream open reading frames (uORFs) to remodel gene expression and adapt to stress. Despite the temporal connection between stress-induced gene expression and SGs, whether and how stress-induced gene mRNAs evade sequestration into SGs and the functional consequences are unclear. To address this, we performed single-molecule fluorescence in situ hybridization of stress-responsive mRNAs in the presence or absence of translation inhibitors that modulate ribosome association on mRNAs. We show that reducing ribosome association on mRNAs increases uORF-harboring mRNA localization to SGs, while increasing ribosome association inhibits their localization to SGs. Next, we tested if uORFs were sufficient to inhibit mRNA localization to SGs using reporter constructs harboring wild-type and mutant uORFs. We observed that uORF reporters were inhibited from localizing to SGs in a ribosome-dependent manner, suggesting that uORF association with ribosomes is sufficient to inhibit mRNA localization to SGs. We further found that a single initiating ribosome inhibits SG formation and mRNA localization to preformed SGs, suggesting that one or more ribosomes prevent mRNA assembly into SGs independently of ribosomal translocation or occupancy across the open reading frame. Together, we provide evidence that uORFs (present in 10-50% of mRNAs) generally inhibit mRNA condensation into ribonucleoprotein granules by ribosome association.
Qiantao Zheng1,2, Shengyi Zhou1,2, Lorelei Baron1, Liangyou Rui1,2,3
Department of Molecular & Integrative Physiology1, Elizabeth Weiser Caswell Diabetes Institute2, Division of Gastroenterology and Hepatology, Department of Internal Medicine3, University of Michigan, Ann Arbor, Michigan, 48109, USA
Abstract:
RNA N6-methyladenosine (m6A) modification emerges to pivotally regulate cell proliferation, differentiation, and functions. The METTL3/METTL14 complex installs m6A on mRNA (m6A writer). YTH family members (e.g. YTHDC1) bind to m6A-marked RNA (m6A readers) and control RNA fate, proteostasis, and cell functions. m6A has emerged as a critical paradigm shaping cell identities and functions. We aimed to delineate the role of hepatic YTHDC1 in metabolic dysfunction-associated steatotic liver disease (MASLD), which has become an important public health problem because of its high prevalence, potential progression to severe liver disease, and association with high risk of developing type 2 diabetes (T2D), dyslipidemia.
We found that mice with hepatocyte-specific deletion of Ythdc1, both males and females on normal chow diet, developed severe MASLD with massive liver steatosis, injury, inflammation, and fibrosis. Hepatocyte-specific reconstitution with YTHDC1, but not m6A binding-defective YTHDC1W377A, fully rescued MASLD. At the molecular level, YTHDC1 directly targeted CD36 (fatty acid transporter) and PPARα genes, thereby suppressing hepatic lipid uptake while stimulating fatty acid β oxidation. Hepatocyte-specific restoration of CD36 and PPARα largely reversed MASLD phenotypes in Ythdc1 knockout mice. Liver YTHDC1 was markedly downregulated in mice and patients with MASLD, likely contributing to disease progression.
In conclusion, we have identified hepatic YTHDC1 as a pivotal m6A reader to control hepatic liver uptake and β oxidation. Downregulation of hepatic YTHDC1 or aberrant m6A pathways play a critical role in MASLD pathogenesis and serve as potential therapeutic targets for MASLD treatment.
Brandon Tepper1, Fatemeh Fattahi1, Laura Vallance1, Julia Holden1, Kareem Hussein1, Joshua Meier1, Ulus Atasoy1,2
1- Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI
2- Division of Allergy-Immunology, Ann Arbor VA Health System, Ann Arbor, MI
Abstract:
The RNA-binding protein HuR (Elavl1) stabilizes mRNA transcripts of transcription factors critical for immune responses. This study evaluates the effects of HuR inhibition using the small molecule KH-3 and a novel transgenic knock in mouse model on GATA3, a master regulator of Th2 cell differentiation.
Splenic CD4+ T cells were pre-incubated with eFluor® 670 dye, treated with KH-3 or inactive KH-3B for 2 hours, and activated with anti-CD3/CD28. On Day 3, flow cytometry revealed reduced cell proliferation, GATA3 expression, and Th2 cytokines IL-4 and IL-13 in KH-3-treated cells. For cytokine analysis, cells were co-cultured with IL-2, IL-4, and anti-IFNγ and re-stimulated with PMA, ionomycin, and BFA, confirming significant reductions in intracellular IL-4 and IL-13 production.
To further investigate HuR’s role, a GATA3 knock-in (KI) mouse model with disrupted HuR-binding sites in GATA3 mRNA was developed. CD4+ T cells from KI and control (GATA3d/d) mice were activated with anti-CD3/CD28 for 4 days. Flow cytometry showed significantly lower IL-4 production in KI cells, with no significant changes in IFN-γ or IL-17 levels, indicating specific targeting of Th2 cytokines.
These findings underscore HuR’s critical role in stabilizing GATA3 mRNA and regulating Th2-mediated responses. Both pharmacological inhibition with KH-3 and genetic disruption of HuR binding reduce GATA3 expression and Th2 cytokine production, identifying HuR as a promising therapeutic target for allergic diseases and other Th2-driven conditions.
K. E. Sala-Hamrick1, K. Wang1,2, B. P. U. Perera1, M. A. Sartor2, D. C. Dolinoy1, and L. K. Svoboda1.
1University of Michigan School of Public Health, Ann Arbor, MI; and 2University of Michigan Medical School, Ann Arbor, MI.
Abstract:
PIWI-interacting RNA (piRNA) are a class of small non-coding RNA that are poorly characterized in the heart. Altered piRNA expression has been reported in the context of cardiovascular disease (CVD), and although exposure to the metal lead (Pb) is strongly associated with CVD risk, no studies have investigated the effects of Pb on cardiac piRNA. The current study provides a comprehensive assessment of piRNA expression in the murine heart and investigates sex-specific effects of human-relevant maternal Pb exposure on offspring cardiac piRNA expression. We utilized cryopreserved adult (5-month) mouse offspring hearts from a model of perinatal Pb exposure (32ppm, resulting in maternal blood Pb levels of 16–60 µg/dL). Small RNA was extracted from whole heart tissues. We performed sodium periodate exclusion of the small RNA, which selects for 2’-O-methylation present in piRNA. Samples were library-prepped and sequenced. In control mice, we found expression of 6,316 piRNA in our combined sex analysis. When comparing Pb-exposed vs. control hearts, we found more potential Pb-induced changes (p-value < 0.05 and absolute logFC > 1) in piRNA expression from female hearts (847) compared to males (187). These piRNAs corresponded in both sexes to biological processes related to heart function and CVD development, including processes related to the mitochondria, energy metabolism, and heart muscle structure and function (FDR < 0.05). These findings suggest a novel epigenetic mechanism by which developmental Pb exposure may impact CVD risk later in life. Future studies will link these molecular changes to Pb-induced alterations in cardiac function.
Megan Medina1, Stephen Deangelo2, Markos Koutmos 1,2
Department of Biological Chemistry1 and Cancer Biology2, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Abstract:
Redox homeostasis is vital for cell survival. An imbalance between reducing and oxidizing species can damage DNA, lipids, and proteins, disrupting overall cellular function. Selenoproteins mitigate oxidative stress by converting reactive oxygen species (ROS) into less reactive molecules. An important step in selenoprotein translation is the modification of the tRNA precursor. AlkBH8 modifies the wobble uridine of tRNA-selenocysteine to recode the mRNA stop codon to selenocysteine. Without the proper modifications at the wobble position, selenocysteine synthesis becomes inefficient, leading to decreased selenoprotein expression, ROS buildup, and eventually cell death.
Preliminary studies have demonstrated overexpression of AlkBH8 in tumor tissue as opposed to normal tissue. Our lab has shown AlkBH8 knockdown/knockout colorectal cancer cell lines (CRC) exhibit decreased selenoprotein translation and significant decrease in CRC growth. Importantly, knockdown of AlkBH8 was shown to have no effect on normal cells, making it an attractive target for anticancer therapy. Currently, we are designing different constructs to increase protein stability for structural characterization. We aim to investigate the mechanism of tRNA modification by AlkBH8 by obtaining a full-length protein structure and identifying crucial residues for catalytic activity. We hypothesize the RNA recognition motif is responsible for substrate recognition and that small-molecule inhibitors of AlkBH8 will result in CRC death.
Kira Holton1,2, Brittany Bowman1,3, Kristin Koutmou2,4-5 and Chase Weidmann1-4
1) Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan, 48109 USA
2) Chemistry-Biology Interface Training Program, NIH GM132046
3) Rogel Cancer Center, University of Michigan Health, Ann Arbor, Michigan 48109 USA
4) Center for RNA Biomedicine, University of Michigan, Ann Arbor, Michigan, 48109 USA
5) Department of Chemistry, University of Michigan College of LSA, Ann Arbor, Michigan 48109 USA
Abstract:
The extent and effect of most human RNAs post-transcriptional modifications is currently unknown. The enzyme PUS7 is responsible for a large fraction of one such RNA modification, the isomerization of uridine to pseudouridine (Ψ). Altered PUS7 activity is implicated in several diseases, but the mechanisms of PUS7-dependent substrate modification and how Ψ contributes to disease pathogenesis are unclear. While PUS7 can modify almost any UNUAR sequence when reconstituted in solution, only a tiny fraction of these sites are modified inside cells. Without understanding the cellular contexts that direct PUS7 target selection, we cannot predict the functional consequences of PUS7-dependent Ψ in RNA. We hypothesize that distinct RNA structural contexts and protein-RNA interactions drive selection of Ψ sites by PUS7 in cells. We are employing live-cell chemical probing and sequencing technologies to identify these cellular contexts. Protein interaction probing (RNP-MaP) in human cells finds that Ψ modification occurs in RNA regions with limited protein binding, when compared to unmodified UNUAR sites. We are profiling protein engagement at these sites in cells lacking PUS7 to determine whether protein occupancy inhibits Ψ modification or alternatively if Ψ modification limits protein binding. Additionally, we developed a cellular luciferase-based reporter assay to measure mRNA expression, processing, and stability in the presence and absence of Ψ. Preliminary data suggests that Ψ-dependent regulation is mRNA-specific. We anticipate that the knowledge generated from this research will allow us to predict novel PUS7-dependent Ψ sites and may be suggestive of a novel gene regulatory mechanism based on RNA modifications.
Elena Glick1, Cathy Smith1,2, Jacob Kitzman1,2
Departments of Human Genetics1 and Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Abstract:
A substantial proportion of protein-coding variants that cause disease do so by disrupting mRNA splicing. For example, essential donor or acceptor mutations are readily classified. However, ~10% of missense variants are splice disruptive, as are ~3% of synonymous variants, which are usually assumed to be benign. Such variants are difficult to recognize – they are numerous but most are individually so rare in the population that no previous evidence is available to guide their interpretation. Here, we focused on the mismatch repair gene MSH2, which underlies the most prevalent familial cancer syndrome (Lynch Syndrome) and is additionally a key biomarker for immunotherapy effectiveness.
Using a massively parallel splicing assay (MPSA), we systematically created every possible single-nucleotide variant within the 16 exons of MSH2 and their proximal flanking introns (+/-25bp). We introduced these as a pooled minigene to human HEK-293 cells, and read out the splicing effect by deep targeted RNA-seq. In preliminary studies, we find 9% of SNVs had splice disruptive effects and caused exon skipping or cryptic splice site usage. Clusters of splicing-disruptive SNVs highlight potential exonic splicing enhancers (ESEs) elements. Our variant-to-splicing effect map shows strong concordance with known splicing variants such as c.1661+2:T>G, c.1759:G>C. We are integrating our map with a database of tens of thousands of clinical RNA-seq results to establish its predictiveness in vivo. We anticipate that this resource will guide interpretation of clinical variants, assisting more accurate diagnosis and enabling prevention and early detection.
Sreeja C Sekhar1, Mukund JayaRaju1, Michele Cusato1, Devisi Goel1, Sandra Orsulic 2, Pilar de Pulento 3 and Analisa DiFeo123
Department of Pathology1 , Department of Obstetrics and Gynecology2, Rogel Cancer Center3 University of Michigan Medical School, UCLA David Geffen School of Medicine4 Sanford Research 5
Abstract:
Targeting microRNAs (miRNAs) has emerged as a promising strategy in cancer therapy. Among these, miR-181a has gained attention for its pivotal role in driving tumor initiation, progression, and metastasis across various cancer models. Elevated miR-181a activity in various cancers underscores its central role in cancer initiation, maintenance, dissemination, and recurrence. By regulating critical signaling pathways such as TGFβ, Wnt, and innate immune signaling, miR-181a fosters tumor growth and immune evasion, positioning it as a prime therapeutic target. Our work uncovers substantial therapeutic benefits of targeting miR-181a in high-grade serous ovarian cancer (HGSC), the most lethal subtype of ovarian cancer. We demonstrate that inhibiting miR-181a reactivates the interferon (IFN) signaling pathway, resulting in robust immune cell activation and significant tumor suppression in vivo. Mechanistically, miR-181a inhibition induces the expression of chemokines and cytokines through STING-dependent anti-inflammatory interferon signaling, effectively halting tumor cell growth both in vitro and in vivo. Furthermore, our studies indicated that the loss of miR-181a enhances the efficacy of commercially available STING agonists, amplifying immune cell infiltration at the tumor site and potentiating anti-tumor immunity. These findings not only advance our understanding of the challenges associated with STING agonist-based therapies but also position miR-181a as a critical therapeutic lever for reprogramming the tumor microenvironment. By disrupting cancer-promoting pathways and restoring immune recognition, targeting miR-181a holds immense potential to improve progression-free survival and deliver transformative outcomes for cancer patients.
Kareem Hussein1, Fatemeh Fattahi1, Julia Holden1, Laura Vallance1, Brandon Tepper1, Joshua Meier1, Steven Huang2, Ulus Atasoy1,3
1- Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI
2- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, University of Michigan Medical School, Ann Arbor, MI
3- Division of Allergy-Immunology, Ann Arbor VA Health System, Ann Arbor, MI
Abstract:
In allergic asthma, airway remodeling and fibrosis are driven by dysregulated gene expression and protein synthesis in lung mesenchymal cells (MCs), also known as fibroblasts. Our study investigates the role of two key RNA-binding proteins, eIF4E and HuR, in the pathogenesis of allergic asthma. eIF4E, located at the 5′ cap of mRNA, facilitates translation initiation and is phosphorylated by MNK1/2. We demonstrate that inhibiting MNK1/2 with eFT-508 significantly reduces eIF4E phosphorylation, resulting in the suppression of autotaxin, ATX (encoded by Enpp2) production by human lung MCs, a protein implicated in fibrosis and airway remodeling. Additionally, HuR (Elavl1), an RNA-binding protein located in the 3′ untranslated region of mRNA, stabilizes Enpp2 mRNA. Using KH-3, a HuR-specific inhibitor, we further validate the contribution of HuR to Enpp2 regulation.
To optimize these therapeutic strategies, we first determined the IC50 values for eFT-508 and KH-3 using the CellTiter-Glo viability assay in human lung fibroblast cell line (CCD-19Lu – CCL-210). Notably, eFT-508 treatment significantly decreased the production of cytokines IL-6 and CCL2 by human lung MCs, highlighting its role in modulating inflammation. Our findings, supported by human lung tissues obtained from the Gift of Life organ repository at the University of Michigan, provide a comprehensive view of how targeting RNA-binding proteins involved in translation and mRNA stability can mitigate the fibrosis linked to airway remodeling. These data emphasize the therapeutic potential of MNK1/2 and HuR inhibition in addressing persistent challenges in allergic asthma pathogenesis.
Amanda Linskens1 and Swathi Yadlapalli1,2
Cellular and Molecular Biology1 and Department of Cell and Developmental Biology2, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Abstract:
Circadian rhythms are regulated by clock neurons, which rely on core clock genes that operate in negative feedback loops to synchronize biological processes with environmental cues. While light is commonly studied as a primary entraining cue, temperature fluctuations are also known to influence circadian behavior. However, the molecular mechanisms of temperature adaptation for the circadian rhythm remain poorly understood. My research, thus far, has focused on the role of temperature in regulating the circadian rhythm through the alternative splicing of the Timeless (TIM) gene, which is a key clock gene in Drosophila melanogaster. Drosophila melanogaster is an excellent model organism for studying circadian temperature adaptation, as its core clock genes are highly conserved in humans, and its body temperature can be easily manipulated through external temperature changes. Immunofluorescent staining and RNA FISH analyses have shown that TIM gene expression, both at the protein and mRNA levels, increases at higher temperatures. Notably, alternative splicing of tim intron #7 (int7) varies with temperature. RNA FISH assays revealed that tim int7 is retained in about half of all tim transcripts at lower temperatures and completely excluded at higher temperatures. These experiments also show cytoplasmic tim mRNA still retaining int7 at lower temperatures, indicating that transcripts containing int7 may be translated into TIM protein. Since the data suggests that tim int7 undergoes temperature-dependent alternative splicing and may affect TIM protein isoform ratio, future projects will explore how thermosensitive splicing of int7 is regulated and its potential role in controlling the circadian rhythm.
Adam B. Wier; Marla R. Gravino; Adam J. Albritton; Brittany S. Morgan, Ph.D.
Department of Chemistry & Biochemistry, University of Notre Dame, South Bend, Indiana, 46637, USA
Abstract:
Covalent chemistry offers two unique dimensions to RNA chemical biology: 1) certain electrophilic small-molecules selectively react with a nucleophile, such as SHAPE reagents with the 2’-hydroxyl and 2) electrophile-nucleophile reactivities can change in supramolecular contexts, informing us about RNA’s higher-order structures (SHAPE), sites of interactions with RNA-binding proteins (CLIP), and potential binding pockets for small-molecule ligands (RBRP). These methods’ success depends on knowledge of each electrophile’s preference for individual nucleophiles. Yet, there has been no comprehensive census of electrophile reactivity with RNA nucleophiles and only a narrow range of RNA-reactive electrophiles have been demonstrated compared to nucleophilic amino acids.
To address this gap in knowledge, I have developed a liquid chromatography-mass spectrometry (LC-MS) platform for screening reactions between electrophilic fragments and 5’-monophosphate ribonucleotides at pHs 7.4-9.0 to mimic standard and perturbed physiological pKas. Reactive electrophiles are then quantified for differences in percentage of covalent bond formation in physiological conditions using high-performance liquid-chromatography coupled with UV-absorbance (HPLC-UV); products are identified using 1H and 13C NMR. We have found that novel chemistries can display specificity for a given nucleotide, broad reactivity, or inertness. To explore how these reactivities change in a structural context, I have also designed a LC-MS platform for the separation and identification of reaction products with a small RNA hairpin loop. This is the first census of electrophile reactivity with ribonucleotides, providing greater context for chemistries used with RNA and broadening the available tools for researchers looking to develop covalent strategies for studying the transcriptome.
Alan Herbert
InsideOutBio, Charlestown, MA 02129
Abstract:
Previously, we have shown that the binding of the interferon induced ADAR1 p150 Zα domain to the left-handed Z-RNA and Z-DNA conformations plays a major role in innate immune responses against viruses and dysfunctional cells. Unresolved is the part played by the Zβ domain, which is present in both the p110 and p150 ADAR1 isoforms. In this talk, we will present new, and unpublished, findings that address the function of Zβ. The data resolve a number of questions about the difference in editing specificity between p150 and p110 isoforms, the true frequency of nonsynonymous edits, and the manner in which ADAR1 impacts alternative splicing. The edits are soft-wired and variable, rather than being fixed and hard-wired. They cause the production of multiple RNA isoforms from a gene, with ADAR1 choreographing the flow of genetic information from flipons to codons.
1 Herbert, A. et al. A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. Proc Natl Acad Sci U S A 94, 8421-8426 (1997).
2 Herbert, A. Mendelian disease caused by variants affecting recognition of Z-DNA and Z-RNA by the Zα domain of the double-stranded RNA editing enzyme ADAR. Eur J Hum Genet 28, 114-117 (2020)
3 Zhang, T. et al. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature 606, 594-602 (2022).
4 Herbert, A. The ancient Z-DNA and Z-RNA specific Zα fold has evolved modern roles in immunity and transcription through the natural selection of flipons. R Soc Open Sci 11, 240080 (2024).
Linda Hongye Li*, Xiaoxiao Wang, Qing Yan, Celetta G. Gateway, Bennett Van Meter, Tulsi Damase, Yi Liang, Elisa Morales, Murilo T. Domingues Bueno, Ewan K.S. McRae, John P. Cooke*
Center for RNA Therapeutics
Abstract:
There is growing interest in mRNA drugs for cardiovascular disease. Typically, mRNA drug substances are generated from linear DNA templates using in vitro transcription (IVT). Thus, linear DNA templates play a critical role in the quality of mRNA drug Substance. A conserved sequence motif ATCTGT was identified as an endogenous T7 RNA polymerase (RNAP) class II pause site decades ago. However, we do not fully understand the impact of this pause site on the IVT process. In the current study, we found that the motif of ATCTGT was not sufficient to cause T7 RNAP to prematurely leave the DNA template. But extra T or A downstream of ATCTGT as ATCTGTt, ATCTGTtt or ATCTGTaaa in DNA templates could cause T7 RNAP stalling and produce short abortive transcripts during IVT. The strength of these T7 RNAP pause site is ATCTGTtt > ATCTGTt > ATCTGTaaa. The location of Class II pause site also plays a role in the strength of terminating transcription in IVT. The more distant the T7 RNAP pause site from the initiation site, the stronger the efficiency of termination. In addition, mRNAs derived from DNA templates harboring T7 RNAP pause sites generated mRNAs with impaired integrity, purity and mRNA yield although no significant effects on mRNA potency and innate immune activation were observed in cells treated with these mRNAs. Our study provides insight into the effect of T7 RNAP class II pause sites that may be useful in designing mRNA substance for better integrity, purity, and higher yield.
Ben T. Pockrass and Rachel O. Niederer
Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan
Abstract:
It is generally understood that mRNAs encoding membrane/secreted proteins are targeted to the endoplasmic reticulum (ER) during early elongation via the signal recognition particle pathway. In this model, translation initiation occurs in the cytoplasm, and mRNA is only targeted to the ER upon emergence of an N-terminal signal sequence during early elongation. However, ribosomes remain in stable association with the ER following translation termination, and these ER-bound ribosomes are capable of direct translation initiation. This includes mRNAs encoding cytoplasmic proteins which do not encode a signal sequence. Despite these findings, the nature of translation initiation at the ER and its regulation are largely unexplored. Because mRNA 5’ untranslated regions (5’ UTRs) are the site of translation initiation, and translation initiation is highly regulated, we hypothesize that 5’ UTR features regulate translation initiation at the ER. One prediction of this hypothesis is that 5’ UTRs from mRNAs encoding membrane proteins would have distinct features, as they uniquely require translation at the ER. A bioinformatic analysis of 5′ UTR features from mRNAs encoding membrane proteins compared to those encoding non-membrane proteins revealed subtle but significant differences in their sequence composition, 5’-terminal nucleotide identity, and RNA binding protein motifs. To systematically identify mRNA 5’ UTR features associated with enhanced/repressed translation initiation at the ER, we are developing a high-throughput method to measure translation initiation rates on ER-bound ribosomes for thousands of unique mRNAs. Discovery of these 5’ UTR features will guide future studies that identify factors regulating translation initiation at the ER.
Bruce A. Sullenger1,2*, Ji Hyun Kim2, Ji-na Kim2, Minyoung Cho2, and Seong-Wook Lee2,3
Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA1, R&D Center, Rznomics Inc., Seongnam, 13486 Republic of Korea2, Dept. of Bioconvergence Engineering, Dankook University, Yongin, 16890 Republic of Korea3
Abstract:
The trans-splicing ribozyme, derived from the Tetrahymena group I intron, was the first RNA-guided endonuclease engineered to edit RNA, and we have been developing it for treating malignant, degenerative, and hereditary disorders. We will describe our efforts to create a trans-splicing ribozyme for editing rhodopsin (RHO) mRNA to treat retinitis pigmentosa (RP). RP is the most common hereditary degenerative eye disease; RHO mutations account for 25~30% of autosomal dominant retinitis pigmentosa (adRP) with ~150 different autosomal dominant mutations described. Fortunately, trans-splicing near the 5’ end of the RHO mRNA can repair any mutant RHO mRNA where the mutation occurs 3’ of the trans-splicing site. Following screening and optimization, we identified a specific RHO-targeting ribozyme that can repair a diverse set of mutant RHO mRNAs with high specificity and efficacy in human cells. To assess in vivo activity, the optimized RHO-targeting ribozyme was delivered by AAV and a single injection into the eyes of P23H or Q344X human Rho (hRHO) knock-in (KI)-adRP mice. We evaluated rod-isolated retinal function via electroretinogram and compared ribozyme-treated with untreated KI-adRP mice for 26 weeks. The ribozyme-treated KI-adRP mice showed significant improvement in retinal function; analysis of retina tissue revealed accurate editing of mutant RHO RNA and significantly thicker outer nuclear layers in treated eyes. Therefore, ribozyme-based RNA editing effectively prevents rod photoreceptor degeneration and preserves retinal function in two different hRHO KI-adRP mouse strains. These results have enouraged us to explore this RNA editing strategy for treating RHO-adRP patients with various mutations.
Grace McIntyre1-3, Jessica Mathew4, Meghana Choragudi5, Aaron Robida, PhD6, Renju Jacob6, Sriram Chandrasekaran7, PhD, Sreeja Sekhar, PhD1-3, Jose Colina, PhD1-3, Zoë Jackson7, PhD, Peter Toogood, PhD5, Analisa DiFeo, PhD1-3*
1Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA 2Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan 48109 3Michigan Ovarian Science and Innovation Consortium 4Chemistry, College of Literature, Science, and the Arts. Ann Arbor, Michigan 48109 5School of Public Health, Ann Arbor, Michigan 48109 6Center for Chemical Genomics, Life Sciences Institute, Ann Arbor, Michigan 48109 7Biomedical Engineering, Ann Arbor, Michigan 48109 8Michigan Drug Discovery, Mary Sue Coleman Hall, Ann Arbor, Michigan 48109 *Corresponding Author: adifeo@umich.edu
Abstract:
miR-181a is a highly conserved microRNA implicated in multiple hallmarks of malignancy, including immune evasion, enhanced proliferation, angiogenesis, EMT, and apoptotic resistance. Its overexpression in many cancers, including colorectal, gastric, prostate, and ovarian, correlates with reduced survival, increased recurrence, and chemoresistance. By modulating pro-survival pathways, including WNT, TGF-β, PTEN, and RAS, and suppressing innate immunity through STING, miR-181a represents a compelling therapeutic target. While nucleotide-based miRNA therapies have advanced, challenges persist in bioavailability, stability, and delivery. Small molecules offer an attractive alternative with better pharmacokinetics and broader translational potential but remain unexplored for miR-181a inhibition. Currently, no therapies target miR-181a, highlighting a significant gap in cancer treatment options. In this study, we exploit miR-181a’s polyvalent therapeutic potential by identifying lead pharmacological inhibitors from a high-throughput screen of >54,000 drug-like compounds using a functional miR-181a biosensor. Structure-activity relationship analysis revealed 49 compounds across three structural classes that reduce miR-181a activity and cell viability. Nearly all these compounds are predicted to be RNA-binding and do not inhibit miR-181a transcription. Our leading six compounds exhibit a dose-dependent correlation between miR-181a activity and cell viability, generally rescue expression of the miR-181a target SFRP4, potently reduce cell viability, and do not interfere with canonical miRNA-mediated mRNA-suppression mediators. Future cell-based profiling will confirm our lead hits and identify their mechanisms of action. Identification of a miRNA-181a small molecule inhibitor will be the first of its kind and will establish a novel and foundational therapeutic avenue to be exploited in miR-181a driven cancers.
Kayla Lenshoek1, Brittany Bowman Ph.D.2, Chase Weidmann Ph.D.2,3,4
1Cellular and Molecular Biology – University of Michigan Medical School, Ann Arbor, MI
2Department of Biological Chemistry – University of Michigan Medical School, Ann Arbor MI
3Center for RNA Biomedicine – University of Michigan, Ann Arbor, MI
4Rogel Cancer Center – University of Michigan Health, Ann Arbor, MI
Abstract:
Long noncoding RNA Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) is linked to the progression of multiple cancer types. Upregulation of MALAT1 is often correlated with aggressive metastasis, and depletion of MALAT1 in cancer cells decreases metastatic potential. Interestingly, in healthy cells and wild-type mouse models, loss of MALAT1 has no effect on viability. The mechanisms by which MALAT1 promotes metastatic activity exclusively in cancer cells is not well understood, and MALAT1’s function in healthy cells is also unknown. Here we aim to uncover the mechanisms by which MALAT1 alters gene regulatory programs to promote metastasis in a lung cancer cell model. We create and validate A549 lung adenocarcinoma cell lines where CRISPR-based gene deletions and insertions alter MALAT1 expression or destabilize the MALAT1 transcript. We find that MALAT1 accumulates at high levels in nuclear speckles, but loss of MALAT1 does not strongly alter nuclear speckle formation. Increased MALAT1 expression promotes a mesenchymal phenotype, whereas reduction in MALAT1 expression promotes a more epithelial cell state. Further, we find that MALAT1 expression is inversely correlated with levels of EZH2 protein, the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2). Consequently, levels of the PRC2 epigenetic mark, Histone H3 Lysine 27 tri- methylation (H3K27me3) are inversely correlated with MALAT1 levels. In line with MALAT1’s pro-metastatic activity, we observe an upregulation in genes and pathways associated with cell adhesion, mobility, and mesenchymal cell identity in MALAT1 overexpression lines. These results are consistent with a model wherein MALAT1 reprograms cancer cells through reorganization of epigenetic marks to promote metastasis through mesenchymal gene programs.
Annyesha Biswas and Saurja DasGupta
Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 45665, USA
Abstract:
The earliest forms of life are thought to have used RNA to constitute their genomes and as enzymes (ribozymes). It is expected that the ability to assemble RNA from shorter pieces would have been the most important enzymatic function in RNA-based biology. In our continuing efforts to understand the scope of RNA-catalyzed RNA assembly, we used directed evolution to convert a ligase ribozyme, which uses RNA substrates that are 5′ activated with the prebiotically relevant phosphorimidazole group, to a new ribozyme, which catalyzes ligation with RNA substrates that are 5′ activated with the biologically relevant triphosphate group. Surprisingly, we isolated four distinct types of ligase ribozymes, in addition to the desired ‘triphosphate ligase’ from that single evolution experiment. Detailed biochemical characterization demonstrated that these ribozymes adopt distinct structures and catalyze RNA ligation via distinct chemical pathways that do not exist in any known protein or RNA-based enzyme in nature. The first ligase class used 5′ phosphorimidazolide RNA substrates for ligation, while the second class facilitated nucleophilic attack between the terminal 2′ OH of the substrate and the 5′ triphosphate group of the ligase ribozyme, only when the substrate possessed a 3′ phosphate group. The third and fourth ligase classes catalyzed branching reactions, which involve distinct internal hydroxyls of the substrate and the 5’ triphosphate group on these ribozymes. The emergence of catalytic diversity from a single ribozyme under constrained selection pressures suggests that RNA is a highly evolvable and versatile scaffold for biocatalysis, bolstering the plausibility of RNA-based primordial life.
Sneha Shah 1, Kevin J Sharp 2, SitharaRaju Ponny 1, Jonathan Lee 3, Jonathan K. Watts 3,4,5, Elizabeth Berry-Kravis 2,6 and Joel D. Richter 1,5
1 Program in Molecular Medicine, University of Massachusetts Chan Medical School; Worcester, MA 01605.
3 RNA Therapeutics Institute, University of Massachusetts Chan Medical School; Worcester, MA 01605.
4 Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School; Worcester, MA 01605.
5 Li Weibo Rare Disease Institute, University of Massachusetts Chan Medical School; Worcester, MA 01605.
2 Department of Pediatrics, Rush University Medical Center; Chicago, IL 60612.
6 Departments of Neurological Sciences and Anatomy and Cell Biology, Rush University Medical Center; Chicago, IL 60612.
Abstract:
Fragile X Syndrome (FXS) is a neurodevelopmental disorder arising from a triplet repeat expansion mutation in the FMR1 gene, resulting in the loss of its protein product, FMRP. While conventionally attributed to FMR1 gene silencing, our recent investigation challenges this notion, revealing mis-spliced FMR1 RNA in a majority of FXS cases. In all FMR1 expressing FXS tissues, FMR1 RNA itself is mis-spliced in a CGG expansion-dependent manner to generate the little-known FMR1-217 RNA isoform, which is comprised of FMR1 exon 1 and a pseudo-exon in intron 1. FMR1-217 is also expressed in FXS premutation carrier-derived skin fibroblasts and brain tissue. We show that in cells aberrantly expressing mis-spliced FMR1, antisense oligonucleotide (ASO) treatment reduces FMR1-217, rescues full-length FMR1 RNA, and restores FMRP (Fragile X Messenger RibonucleoProtein) to normal levels. This discovery offers potential therapeutic opportunities. Moreover, our research has unveiled a scarcity of metabolites in FXS human patient brain tissues, suggesting an association between FMRP deficiency and metabolic dysregulation. Additionally, preliminary findings suggest a correlation between FMRP expression levels and the extent of metabolite imbalance in FXS cells. We propose that reinstating FMRP expression may alleviate metabolite imbalances in FXS, thus addressing a potential underlying mechanism contributing to the disorder’s pathophysiology.
Shuang Li1, Kaylee N. Carter1, Li Lai1, John P. Cooke1
1Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, Texas
Background:
Angiogenesis is an endogenous response to ischemia, yet the underlying epitranscriptomic regulation remains unclear. Here we demonstrate that ischemic angiogenesis requires a specific chemical modification of endogenous messenger RNA (mRNA). The N6-methyladenosine (m6A) of mRNA is a prevalent post-transcriptional modification of native mRNA and is known to influence various biological processes. METTL3 and METTL14 form the core m6A methyltransferase complex, which catalyzes the deposition of m6A on mRNA. However, the role of m6A in ischemic response has not been studied previously.
Methods:
We utilized a murine hindlimb ischemia model to evaluate vascular recovery post-ischemia with blood flow monitored using laser Doppler imaging. m6A RNA modification levels were quantified via RNA dot blot and ELISA-based assays. Capillary density was quantified through immunostaining for CD31 and CD144. To investigate angiogenic transdifferentiation during vascular recovery, we used constitutive (Fsp1-Cre: R26R-EYFP) and inducible (Col1A2-iCre: R26R-tdTomato) fibroblast lineage-tracing mice. Additionally, a small molecule-based protocol was applied to transdifferentiate human fibroblasts into endothelial cells in vitro.
Results:
At day 7 post femoral artery ligation, m6A levels were significantly elevated in ischemic muscle, particularly in fibroblasts. Inhibition of m6A, either by a METTL3 pharmacological inhibitor or fibroblast-specific METTL14 knockout, impaired perfusion recovery, as indicated by reduced blood flow, increased tissue damage, and decreased capillary density. Lineage-tracing studies revealed that impaired recovery was associated with reduced angiogenic transdifferentiation, evidenced by fewer fibroblast-derived endothelial cells. Moreover, in human fibroblasts, suppression of m6A hindered, while enhancement of m6A promoted fibroblast-to-endothelial cell transdifferentiation.
Conclusions:
RNA m6A modification plays a crucial role in microvascular restoration partially through angiogenic transdifferentiation and represents a potential therapeutic target for vascular recovery in ischemic conditions.
Srijoni Majhi1*, Pronay Roy1*, Lydia Freddolino2, E. Neil G. Marsh1,2
Departments of Chemistry1 and Biological Chemistry1,2, University of Michigan and University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Abstract:
Autoinflammatory diseases are characterized by dysregulated interferon (IFN) signaling. These diseases are associated with high expression of Interferon Stimulated Genes (ISGs) and mitochondrial abnormalities such as transcriptional downregulation of mitochondrially encoded genes (mt-genes). However, due to the complexity of the IFN response—hundreds of ISGs are currently known to be regulated—the mechanism of mt-gene downregulation has remained unexplained.
Viperin (RSAD2) is an ISG with antiviral properties that is conserved across all domains of life. Our research shows that viperin via its enzymatic product — 3′-deoxy-3′,4′-didehydrocytidine triphosphate (ddhCTP) suppresses mitochondrial transcription by causing premature chain termination. We have found that both transient expression of viperin and supplementation of ddhC (nucleoside precursor to ddhCTP) in culture media downregulates mt-gene expression in various cell lines. The pattern of mRNA downregulation fits well with a simple, quantitative model describing chain-termination during bidirectional transcription within the mitochondria. In vitro experiments with purified POLRMT demonstrate that ddhCTP competes effectively with CTP, leading to its misincorporation into growing RNA transcripts. Transcriptomic analysis corroborated with overall downregulation of mt-genes and maximal downregulation of genes in the middle of the mt-genome. Additionally, differential gene expression analysis revealed enrichment of genes in innate immunity and several long non-coding RNAs implicated in acute myeloid leukemia. These findings reveal a new molecular mechanism for mitochondrial transcriptional regulation that explains the reduction of mt-genes in response to the chronic IFN stimulation, characteristic of inflammatory diseases.